

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

High prevalence of hyperuricemia and the impact on non-valvular atrial fibrillation: Results from the Guangzhou Heart Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028007
Article Type:	Research
Date Submitted by the Author:	20-Nov-2018
Complete List of Authors:	<p>Lin, Wei-dong; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences Deng, Hai; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Guo, Pi Liu, Fangzhou; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Chen, Ruyin; Shantou University Medical College, Preventive Medicine Fang, Xianhong; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Zhan, xianzhang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Liao, Hongtao; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Huang, Wenxiang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Liu, Yang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Wang, Feng; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences Zheng, Murui; Guangzhou Center for Disease Control and Prevention Liu, Huazhang; Guangzhou Center for Disease Control and Prevention Huang, Jun; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Wei, Wei; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Xue, Yumei; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Wu, Shu-lin; Department of Cardiology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China</p>
Keywords:	Cardiac Epidemiology < CARDIOLOGY, EPIDEMIOLOGY, CARDIOLOGY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

High prevalence of hyperuricemia and the impact on non-valvular atrial fibrillation: Results from the Guangzhou Heart Study

Weidong Lin^{1, a}, Hai Deng^{1, a}, Pi Guo^{1, b}, Fangzhou Liu^a, Ruyin Chen^c, Xianhong Fang^a, Xianzhang Zhan^a, Hongtao Liao^a, Wenxiang Huang^a, Yang Liu^a, Feng Wang^a, Murui Zheng^d, Huazhang Liu^d, Jun Huang^a, Wei Wei^a, Yumei Xue^{*, a}, Shulin Wu^{*, a}.

^a Department of cardiology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

^b Department of Preventive Medicine, Shantou University Medical College, Shantou, China

^c Department of Clinical Medicine, Shantou University Medical College, Shantou, China

^d Guangzhou Center for Disease Control and Prevention, Guangzhou, China

Address for correspondence:

Yumei Xue, MD

Department of Cardiology

96 Dongchuan Road, Yuexiu District , Guangzhou City , Guangdong Province, China

Phone: +8613570082363

E-Mail: xymgdc@163.com

Shulin Wu, MD, FACC

Department of Cardiology

96 Dongchuan Road, Yuexiu District , Guangzhou City , Guangdong Province, China

Phone: +8613902255336

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

E-Mail: drwushulin@163.com

Word count: 2980

For peer review only

ABSTRACT

Objectives: Epidemiological features of hyperuricemia (HUA) have regional difference. The prevalence of HUA and non-valvular atrial fibrillation (NVAf) in southern China is not reported.

Design: A cross-sectional study.

Setting and participants: A total of 11488 permanent residents aged 35 or above from urban and rural areas of Guangzhou city were enrolled in this study. A questionnaire was used to compile each participant's demographic information and relevant epidemiological factors for HUA and NVAf. A range of blood tests were assessed and single-lead 24 hours ECG was performed for all participants.

Main outcome measures: The criterion of diagnosis of NVAf followed the 2014 AHA/ACC/HRS guideline. HUA was defined as serum uric acid (SUA) $>420\mu\text{mol/L}$ in males and $>360\mu\text{mol/L}$ in females.

Results: The incidence of HUA was 39.6% (44.8% in male and 36.7% in female, respectively) and 144 residents (1.25%) were found with NVAf. Prevalence of HUA of women increased with age but maintained a steady high level in men. After adjusting for potential confounding factors, factors including age, living in urban areas, alcohol consumption, central obesity, elevated fasting plasma glucose, elevated blood pressure, reduced HDL cholesterol and raised triglycerides level were associated with the increased risk of HUA. Residents with HUA had a markedly higher risk of NVAf. According to subgroup analysis separated by sex, the variable of SUA had a modest predictive value of NVAf in females while the value was mild in males.

Conclusions: The prevalence of HUA was extremely high among citizens of southern China. HUA was strongly related to NVAf especially in Chinese females according to our study.

Strengths and limitations of this study:

- The study investigates the prevalence of hyperuricemia and its impact on non-valvular atrial fibrillation.
- This cross-sectional study includes a large cohort from urban and rural areas of Guangzhou.
- The surveyed areas are all randomized to increase reliability.
- This study doesn't include resident under age 35.
- This is a cross-Sectional study and the results need to be further clarified through prospective studies.

INTRODUCTION

The prevalence of hyperuricemia (HUA) ranged from 13.3% to 21.6% and showed sex related difference according to reports from different countries or regions [1, 2]. Regional difference could also be observed in same country, which strongly implied the impact of surrounding, climate, economic state and especially the dietary habits [3, 4]. A number of epidemiologic studies have reported a relation between SUA level and variety cardiovascular conditions such as hypertension, coronary artery disease, vascular dementia, metabolic syndrome, cerebrovascular disease and kidney disease, but the relative association remains controversial according to other studies like Framingham Heart Study which argued that uric acid is not a risk factor for cardiovascular disease [5]. Prevalence of HUA in typical southern China city like Guangzhou has not been reported. As a region with unique dietary habit and climate, prevalence of HUA and its association with cardiovascular disease should provide additional information in this study field.

Atrial fibrillation (AF) has been well known as the most common clinical cardiac arrhythmia which contributes to increased morbidity and mortality especially in those with cardiovascular risk factors [6]. As previously reported, number of AF patients is estimated to rise to 9 million by 2050 in China [7] and the increasing prevalence of AF also makes it a global health problem [8, 9]. The association between AF and HUA has been reported a lot [10], but whether SUA is one of risk factors of AF remains under discussion.

We conducted this cross-sectional population-based study to reveal the prevalence of HUA and its association with non-valvular AF(NVAF) in Guangzhou residents.

Materials and methods

Study population

We conducted a cardiovascular epidemiological survey (the Guangzhou Heart Study) from July 2015 to August 2017 in Guangzhou. Two streets (Dadong Street and Baiyun Street) were randomized selected to stand for urban areas while one street and two towns (Xiaoguwei Street, Xinzao Town and Nancun Town) were chosen as rural areas. A sample of permanent residents aged 35 and above was selected by cluster sampling in each community of the selected areas demonstrated above.

The residents in the study sites were invited to participate in this study by 3-round mobilization via door-to-door visits or telephone appointments. Individuals enrolled need to meet the criterions as: 1) Residents who were registered in the Guangzhou Household Register; 2) Aged 35 years or older; 3) Living in the selected communities for at least 6 months by the day they participant the survey. Residents were excluded when meet criterions as: 1) mental or cognitive disorders including dementia, disturbance of understanding, and deaf-mutters; 2) mobility difficulties including high paraplegia; 3) pregnant or lactating women; 4) malignant tumors under treatment; 5) floating people including those who rented the houses or apartments; 6) non-responders during the 3-round mobilization.

This study was approved by the Guangzhou Medical Ethics Committee of the Chinese Medical Association. All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Data collection

1
2
3
4 The residents in the study sites were invited to participate in this study by 3-round mobilization
5
6 via door-to-door visits or telephone appointments. A structured and interviewer-administered
7
8 questionnaire was used to survey each participant's demographic information, personal history of
9
10 disease, living habit, family history and emotional status. Physical examination including
11
12 measurement of waist circumference, height, weight, blood pressure, heart rate and body fat were
13
14 performed by standard instruments and protocols. Blood samples were collected and tested
15
16 according standardized procedure by authorized medical laboratory. Electrocardiograph (ECG)
17
18 and 24-hour single-lead ECG were recorded in each participant and reports were assessed by two
19
20 independent cardiologists. Detailed method has been reported in Deng et al's work which was
21
22 accepted by *Scientific Reports* just now.
23
24
25
26
27
28
29
30
31

32 **Cohort definition**

33
34
35 Subjects were diagnosed with NVAf meeting any one criterion as following: 1) ECG screening
36
37 of subject shows AF pattern; 2) ECG screening does not find AF but subject has AF history with
38
39 evidence; 3) 24 hours single-lead ECG record shows AF episodes. The criterion of diagnosis of
40
41 NVAf followed the 2014 AHA/ACC/HRS guideline^[6]. ECG and single-lead 24 hours ECG
42
43 record were performed by well-trained physicians and AF diagnosis were determined by two
44
45 specific electrophysiological experts. HUA was defined as serum uric acid (SUA) >420 μ mol/L in
46
47 males and >360 μ mol/L in females. The metabolic syndrome (MetS) is defined as having at least
48
49 three or five characteristic signs as following^[7]: Abdominal obesity (defined as waist
50
51 circumference \geq 90cm for men and \geq 80cm for women). Raised Triglycerides level: Triglycerides >
52
53 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality. Reduced HDL
54
55
56
57
58
59
60

1
2
3
4 cholesterol: < 40 mg/dL (1.03 mmol/L) in males and < 50 mg/dL (1.29 mmol/L) in females or
5
6 specific treatment for this lipid abnormality. Raised blood pressure (BP): systolic BP > 130
7
8 mmHg or diastolic BP > 85 mmHg or treatment for previously diagnosed HTN. Raised fasting
9
10 plasma glucose (FPG): FPG > 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 DM.
11
12
13
14
15
16

17 **Patient and Public Involvement**

18
19 The role of patients in this study was residents. They were not involved in the development of the
20
21 research question and outcome measures. All residents were informed of the right to inquire their
22
23 data and test results. If residents were diagnosed with cardiovascular disease, they were notified
24
25 to Guangdong general hospital for further treatment by phone.
26
27
28
29
30
31

32 **Statistical analysis**

33
34 Numerical variables were expressed as mean±standard deviation and categorical variables were
35
36 expressed as percentage. Comparison between two groups were made using the Student *t* test or
37
38 chi-square tests, as appropriate. Multivariate logistic regression models were developed to
39
40 investigate the risk factors for HUA and the associations between the prevalence of Non-valvular
41
42 AF and HUA. The odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs)
43
44 were calculated to assess the associations. Receiver-operating characteristic (ROC) analyses were
45
46 used to detect the cutoff value of SUA in prediction of non-valvular AF. SAS software version
47
48 9.3 (SAS Institute Inc.; Cary, NC) was used for the statistical analyses. All statistical tests were
49
50 2-sided, and a $P < 0.05$ was statistically significant.
51
52
53
54
55
56
57
58
59
60

RESULTS

Baseline characteristics

The study recruited 11488 residents and the incidence of HUA was 39.6% (44.8% in male and 36.7% in female). Among women, the SUA value and the incidence of HUA increased with age. In contrast, the SUA value and incidence of HUA were not affected by age among men [Figure 1]. The incidence of HUA in urban areas is higher than rural areas (Table 1). According to the medical history, the proportion of male with HUA was significantly higher than female. The age was significantly higher in residents with HUA. Regardless of gender, the abdominal circumference and body mass index were significantly greater in residents with HUA. Larger proportion of Non-valvular AF, HTN, DM, Central obesity, Elevated BP, Stroke/Transient Ischemic Attack (TIA) were observed in residents with HUA. According to laboratory examinations, the Hemoglobin (HGB), Platelet (PLT), Red blood cell counts (RBC), Low-density lipoprotein (LDL), Cholesterol (CHOL), fasting plasma glucose (FGP) were significantly higher while Creatinine, High-density lipoprotein were significantly lower in residents with HUA. Significant larger proportion of Reduced HDL cholesterol, Raised TG level and MetS were observed in residents with HUA.

Table1 Baseline characteristics of residents with or without Hyperuricemia

	Total (n=11488)	HUA (n=4547)	No HUA (n=6941)	P-value
<i>Clinical characteristics</i>				
Male (n, %)	4047(35.2)	1814(39.9)	2233(32.2)	<0.01
Age (yrs)	58.22±11.74	59.98±11.44	57.06±11.79	<0.01
Urban (n, %)	5403(46.9)	2210(48.6)	3193(46.0)	0.01
Systolic Bp (mmhg)	130.51±20.52	134.16±20.39	128.13±20.25	<0.01

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Diastolic Bp (mmhg)	80.70±11.61	82.30±11.60	79.62±11.49	<0.01
Non-valvular AF (n, %)	144(1.3)	91(2.0)	53(0.8)	<0.01
Hypertension (n, %)	3377(29.4)	1744(38.4)	1633(23.5)	<0.01
Diabetes mellitus (n, %)	1050(9.1)	528(11.6)	522(7.5)	<0.01
Elevated BP (n, %) &	6698(58.3)	3092(68.0)	3606(52.0)	<0.01
BMI (kg/m ²)	24.01±3.55	25.08±3.55	23.32±3.37	<0.01
Abdominal circumference (cm)	84.41±10.10	87.69±9.61	82.26±9.83	<0.01
Male	84.41±10.11	87.71±9.63	82.26±9.83	<0.01
Female	82.76±9.98	86.36±9.64	80.66±9.56	<0.01
Central obesity (n, %) §	6183(53.8)	2984(65.6)	3199(46.1)	<0.01
Heart failure (n, %)	114(1.0)	50(1.1)	64(0.9)	0.39
Stroke/TIA (n, %)	274(2.4)	128(2.8)	146(2.1)	0.02
Alcohol consumption (n, %)	2467(21.5)	1060(23.3)	1391(20.0)	<0.01
Smoking (n, %)	2451(21.3)	1114(24.5)	1353(19.5)	<0.01
Laboratory examinations				
HGB (g/L)	138.74±14.07	140.14±14.11	137.83±13.97	<0.01
PLT (10 ⁹ /L)	243.78±60.67	245.42±61.76	242.71±59.93	0.019
RBC (10 ¹² /L)	4.76±0.64	4.80±0.65	4.73±0.63	<0.01
HDL cholesterol(mmol/L)	1.49±0.55	1.36±0.51	1.58±0.56	<0.01
Reduced HDL cholesterol (n, %) □	2589(22.5)	1369(30.1)	1220(17.6)	<0.01
LDL (mmol/L)	3.64±1.03	3.72±1.04	3.58±1.01	<0.01
CHOL (mmol/L)	5.486±1.13	5.57±1.17	5.42±1.11	<0.01
TG (mmol/L)	1.696±1.43	1.47±1.06	2.05±1.18	<0.01
Raised TG level (n, %) £	3787(33.0)	2140(47.1)	1647(23.7)	<0.01
FPG (mmol/L)	5.586±1.57	5.69±1.52	5.51±1.60	<0.01
Elevated FPG (n, %) ¶	3375(29.4)	1653(36.4)	1722(24.8)	<0.01
Uric acid (umol/L)	367.20±98.39	460.60±72.77	306.01±55.62	<0.01
Male	367.00±98.30	460.60±72.70	306.01±55.63	<0.01
Female	340.76±89.40	434.37±64.43	286.30±46.52	<0.01

Creatinine(umol/L)	76.89±25.45	83.78±33.25	72.36±17.22	<0.01
Mets (n, %)	3519(30.6)	2014(44.3)	1505(21.7)	<0.01

BP: Blood pressure; TIA: Transient Ischemic Attack; BMI: Body Mass Index; HGB: Hemoglobin; PLT: Platelet; RBC: Red blood cell counts; FPG: fasting plasma glucose; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CHOL: Cholesterol; Mets: Metabolic syndrome

§: Central obesity was defined as waist circumference >85cm for men and >80cm for women

¶: Elevated FPG was defined as fasting plasma glucose > 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes.

&: Elevated BP was defined as systolic BP > 130 or diastolic BP > 85 mm Hg or history of hypertension

□: Reduced HDL was defined as HDL <40 mg/dL (1.03 mmol/L) in men or <50 mg/dL (1.29 mmol/L) in women or specific treatment for this lipid abnormality.

£: Raised Triglycerides level was defined as Triglycerides > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality.

Analysis of prevalence risk of hyperuricemia.

We performed logistic regression analyses to evaluate the risk factors for hyperuricemia (Table 2). After adjusting for possible confounding factors, age (per 10years, OR 1.10, 95% CI 1.06-1.14), living region (urban, OR 1.15, 95% CI 1.06-1.25), alcohol consumption(OR 1.12, 95% CI 1.01-1.24), central obesity(OR 1.82, 95% CI 1.67-1.99), Elevated FPG(OR 1.18, 95% CI 1.08-1.29), Elevated BP(OR 1.34, 95% CI 1.22-1.46), Reduced HDL(OR 1.27, 95% CI 1.15-1.71), Raised Triglycerides level (OR 2.14, 95% CI 1.97-2.35) were strongly associated with the risk of hyperuricemia.

Table2. Analysis of prevalence risk of hyperuricemia in multiple logistic regression model.

Model [†]	Odds ratio	95% confidence interval	P-value
Age (per 10years)	1.10	1.06-1.14	<0.01
Living area(urban)	1.15	1.06-1.25	<0.01
Alcohol consumption	1.12	1.01-1.24	0.03
Central obesity	1.82	1.67-1.99	<0.01
Elevated FPG	1.18	1.08-1.29	<0.01
Elevated BP	1.34	1.22-1.46	<0.01
Reduced HDL	1.27	1.15-1.41	<0.01

Raised Triglycerides level 2.14 1.96-2.35 <0.01

FPG: fasting plasma glucose; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CHOL: Cholesterol;

‡ Adjusted risk factors: age (per 10years), living region, education level, marriage status, smoking status, alcohol consumption, central obesity, Elevated FPG, Elevated BP, Reduced HDL, Raised Triglycerides level

Predictive Value of Hyperuricemia on Non-valvular AF.

The adjusted multivariate logistic regression analysis showed that age (per 10 years) (OR 2.31, CI 1.93-2.78), female gender (OR 2.21, CI 1.45-3.36), central obesity (OR 1.93, CI 1.29-2.90, P<0.01), HUA (OR 2.19, 95% CI 1.53-3.12) and history of heart failure (OR 5.13, CI 2.52-10.43) were risk factors for AF prevalence (Table3). ROC curves were generated for the SUA in different gender to determine their diagnostic capability for NVAf. The area under the ROC curve (AUC) for SUA was 0.72 (95% CI: 0.79–0.91) in female and 0.58 (95% CI: 0.51–0.62) in male [Figure 2].

Table3. Increasing odds ratio for non-valvular AF with hyperuricemia.

Variables [⊙]	Odds ratio	95% confidence interval	P-value
Age (per 10years)	2.31	1.93-2.78	<0.01
Gender(female)	2.21	1.45-3.36	<0.01
Central obesity	1.93	1.29-2.87	<0.01
HUA	2.19	1.53-3.12	<0.01
Heart failure	5.13	2.53-10.43	<0.01

AF: atrial fibrillation; HUA: Hyperuricemia

⊙ Adjusted risk factors: age (per 10years), gender, heart failure, smoking status, alcohol consumption, central obesity, Elevated FPG, Elevated BP, Reduced HDL, Raised Triglycerides level and Hyperuricemia

DISCUSSION

1
2
3
4 Three main findings can be obtained from this study. Firstly, the prevalence of HUA was 39.6%
5
6 (44.8% in male and 36.7% in female) and sex related differences were found in residents with
7
8 HUA; Secondly, the age, living in urban, alcohol consumption, central obesity, elevated FPG,
9
10 elevated BP, reduced HDL, raised and triglycerides level were strongly associated with risk of
11
12 HUA; Thirdly, residents with HUA had a markedly increased risk of non-valvular AF, but SUA
13
14 had moderate predictive value for Non-valvular AF only in female.
15
16
17
18
19
20
21

22 **The incidence of Hyperuricemia**

23
24 Regional differences of prevalence of HUA have been reported broadly. According to Liu's
25
26 review^[11], the prevalence of HUA in mainland China from 2000-2014 was 13.3% (19.4% in
27
28 men and 7.9% in women). Data of some Chinese literatures showed that prevalence in
29
30 Guangdong province ranged from 15 to 20%^[11]. The National Health and
31
32 Nutrition Examination Survey (NHANES) in United States demonstrated that prevalence of
33
34 HUA was 21.2% in men and 21.6% in women^[2]. In other region of Asia like Japan and Taiwan,
35
36 a similar prevalence as that of the USA was reported^[12, 13]. In this study, the prevalence of HUA
37
38 in Guangzhou area was 39.6% (44.8% in male and 36.7% in female), which was extremely high
39
40 compared to previous report. The traditional dietary habits of Guangzhou residents might be one
41
42 of the important reasons. Sex related differences of prevalence of HUA was also observed in our
43
44 study. The prevalence of HUA increased with age in women while maintained steady high level
45
46 in men regardless age. A rapidly accelerated prevalence of HUA in women after 55 years old was
47
48 observed and the prevalence was similar to or even higher than that of men after 65 years old.
49
50 This situation can be possible explained by greatly decreased estrogen level in postmenopausal
51
52
53
54
55
56
57
58
59
60

1
2
3
4 women^[14]. Estrogen might promote excretion of SUA due to its effect on the post-secretory
5
6 tubular reabsorption of SUA, which was confirmed by the effectiveness of hormone replacement
7
8 therapy in reducing SUA^[15, 16].
9
10
11
12
13

14 **Risk factors of Hyperuricemia**

15
16
17 Due to the increasing incidence of HUA, it is of great clinical significance to search for risk
18
19 factors for HUA. Risk factors for hyperuricemia might vary among different ethnic groups. In
20
21 this study, age, alcohol consumption, central obesity, Elevated FPG, Elevated BP, Reduced HDL
22
23 and Raised Triglycerides level were strongly associated with the risk of HUA. Previous studies
24
25 showed that hypertriglyceridemia was strongly associated with risk of HUA^[17]. The Seychelles
26
27 Heart Study II revealed the conclusion that high serum TG level was the strongest predictor of
28
29 HUA^[18], our study reached the same conclusion. The mechanism of hypertriglyceridemia
30
31 leading to HUA might be related to lifestyle^[18] or genetic factors^[19]. Central obesity, Elevated
32
33 FPG, Elevated BP, Reduced HDL and Raised Triglycerides level were all the diagnostic
34
35 component of MetS, it was easy to find that hyperuricemia was closely related to MetS. Yuan's
36
37 study showed that MetS was 10 times higher in those having SUA ≥ 10 mg/dL compared to those
38
39 with SUA < 6 mg/dL in adults with normal body mass index^[20]. A meta-analysis of more than
40
41 fifty-four thousand participants showed that elevated SUA was associated with increased risk of
42
43 MetS^[21]. SUA and MetS often accompany each other and promote the occurrence of
44
45 cardiovascular disease.
46
47
48
49
50
51
52
53
54
55
56
57

58 **Hyperuricemia and Non-valvular Atrial fibrillation**

59
60

1
2
3
4 HUA showed a strong relationship with AF in our study. As reported previously, HUA was
5
6 associated with endothelial dysfunction, oxidative stress, abnormal high levels of inflammatory
7
8 markers and insulin resistance^[22-24]. Result of the Atherosclerosis Risk In Communities (ARIC)
9
10 study^[25] showed that HUA was associated with a greater risk of new onset AF. Unlike our study,
11
12 the ARIC study enrolled patients aged from 45 to 64 years. Another study from Taiwan^[26]
13
14 showed that serum UA was significantly correlated with left atrial diameter and HUA was a
15
16 significant risk factor for new-onset AF in the multivariate Cox regression analysis, but patients
17
18 were defined as HUA only when they suffered from gout attack while asymptomatic patients
19
20 were not screened out in this study. Differently, we assessed uric acid metabolism status of
21
22 residents by testing blood uric acid levels in the fasting state. A recent Chinese report also
23
24 showed that HUA increased AF risk by 2 folds in elderly southwestern residents^[27]. Except for
25
26 the age, only 7.6% AF residents of this study presented with HUA while there was 63.2% of our
27
28 cohort. Interestingly, the prevalence of HUA was very high in our study, which might be related
29
30 to eating habits with high intake of overcooked soup and seafood of Guangzhou citizens^[28].
31
32 Mechanisms underlying the association between urea acid and AF remain unclear but previous
33
34 report showed that elevated UA was associated with vasoconstriction, vascular smooth muscle
35
36 cell proliferation, endothelial dysfunction, oxidative stress, local inflammation and insulin
37
38 resistance^[29].
39
40
41
42
43
44
45
46
47
48
49

50
51 Sex related difference with cardiovascular events has been reported^[30]. In Suzuki's and the
52
53 Atherosclerosis Risk in Communities (ARIC) Study, the result showed that elevated SUA was
54
55 associated with a higher risk of AF particularly in women. Both SUA and HUA had moderate
56
57 predictive value of AF in the result of our study. It's worth noting that SUA had higher AUC than
58
59
60

1
2
3
4 HUA, which means continuous uric acid (UA) level had better predictive value of AF than a
5
6
7 cutoff value. As reported previously, the relationship between UA and cardiovascular disease
8
9
10 could be observed with normal to high serum level (310-330umol/L) of UA^[31-33] and each
11
12 1mg/ml increase in UA level was associated with 12% to 20% increase in the risk for
13
14 cardiovascular and all-cause mortality respectively^[34]. Therefore, UA level might have very
15
16 strong relation with AF. The underlying mechanisms of sex related difference of HUA and AF
17
18 remains unknow. A study showed that HUA was associated with endothelial dysfunction in
19
20 post-menopausal women, suggesting that HUA could be an independent risk factor for
21
22 cardiovascular disease including AF, particularly in postmenopausal women^[35].
23
24
25
26
27
28
29

30 **Limitations**

31
32 There are two limitations of the study. This study doesn't include resident under age 35, it is
33
34 unclear whether residents aged less than 35 also have a high incidence of HUA, which requires
35
36 further research confirmation. Our research is only a cross-Sectional study, the results of this
37
38 study need to be further clarified through prospective studies and follow-up.
39
40
41
42
43
44

45 **CONCLUSIONS**

46
47 This large-scale cross-sectional study demonstrates that there is a high prevalence of HUA with
48
49 sex related difference in Guangzhou residents. Growing age, living in urban, alcohol
50
51 consumption and component of MetS increase the risk of HUA. Residents with HUA had a
52
53 markedly increased risk of AF and the uric acid level had moderate predictive value for NVAF
54
55 only in women.
56
57
58
59
60

Contributors

W.L., H.D., Y.X. and S.W. conceived the study, analyzed data, interpreted results and drafted the manuscript. P.G., R.C., F.L., X.F., X.Z., H.L., W.H., Y.L., F.W., M.Z., H.L, J.H. collected data and completed the survey.

Acknowledgments

The authors thank all the residents involved in this study for their cooperation.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship or publication of this article.

Funding

This work was supported by National Nature Science Foundation of China (No.81370295), Guangzhou Science and Technology Project (No. 201508020261 and No. 2014Y200196), Science and Technology Program of Guangdong Province, China (No.2017A020215054), Science and Technology Planning of Guangzhou City, China (No.2014B070705005).

DATA SHARING STATEMENT

The data is available from the corresponding author on reasonable request.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Figure legends**
4
5

6 **Figure 1.** Different prevalence of HUA among male and female in stepwise age categories
7
8

9 HUA, hyperuricemia;
10

11 Age categories, every ten years from 35 years old.
12
13
14
15
16

17 **Figure 2.** Predictive value of HUA or SUA for AF in male and female.
18

19 A, receiver operating characteristic (ROC) curve of HUA or SUA for AF in male; B, ROC curve
20
21
22 of HUA or SUA for AF in female;
23
24

25 HUA, hyperuricemia; SUA, serum uric acid; A, AUC (area under curve).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:


- [1] B L, T W, Hn Z, Ww Y, et al. The prevalence of hyperuricemia in China: a meta-analysis. *BMC public health*. 2011;**11**(1):832 'doi': 10.1186/1471-2458-11-832.
- [2] Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum*. 2011;**63**(10):3136-3141 'doi': 10.1002/art.30520.
- [3] Strasak A, Ruttman E, Brant L, Kelleher C, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. *Clin Chem*. 2008;**54**(2):273-284 'doi': 10.1373.
- [4] Ndrepepa G. Uric acid and cardiovascular disease. *Clinica Chimica Acta*. 2018; **484**:150-163 'doi': 10.1016/j.cca.2018.05.046.
- [5] Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. *N Engl J Med*. 2008;**359**(17):1811-1821 'doi': 10.1056/NEJMra0800885.
- [6] January CT, Wann LS, Alpert JS, Calkins H, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation*. 2014;**130**(23):2071-2104 'doi': 10.1161/CIR.0000000000000040.
- [7] Hajhosseiny R, Matthews GK, Lip GY. Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic. *Heart Rhythm*. 2015;**12**(11):2332-2343 'doi': 10.1016/j.hrthm.2015.06.038.
- [8] Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. *Stroke*. 1996;**27**(10):1765-1769.
- [9] Friberg J, Buch P, Scharling H, Gadsbøll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. *Epidemiology*. 2003;**14**(6):666-672 'doi': 10.1097/01.ede.0000091649.26364.c0.
- [10] Tamariz LMM, Agarwal SMM, Soliman EZMM, Chamberlain AMP, et al. Association of Serum Uric Acid With Incident Atrial Fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study). *American Journal of Cardiology*, The. 2011;**108**(9):1272-1276 'doi': 10.1016/j.amjcard.2011.06.043.
- [11] Liu R, Han C, Wu D, Xia X, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. *BioMed Research International*. 2015;**2015**:1-12 'doi': 10.1155/2015/762820.
- [12] Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S. Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. *Hypertens Res*. 2004;**27**(4):227-233.
- [13] Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. *Asia Pac J Clin Nutr*. 2011;**20**(2):301-308.
- [14] Guan S, Tang Z, Fang X, Wu X, et al. Prevalence of hyperuricemia among Beijing post-menopausal women in 10 years. *Arch Gerontol Geriatr*. 2016; **64**:162-166 'doi': 10.1016/j.archger.2016.02.002.
- [15] Anton FM, Garcia PJ, Ramos T, Gonzalez P, Ordas J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. *Metabolism*. 1986;**35**(4):343-348.
- [16] Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. *Lancet*. 1999;**354**(9179):650 'doi': 10.1016/S0140-6736(99)92381-4.
- [17] Liu CS, Li TC, Lin CC. The epidemiology of hyperuricemia in children of Taiwan aborigines. *J Rheumatol*. 2003;**30**(4):841-845.
- [18] Chelchowska M, Ambroszkiewicz J, Gajewska J, Laskowska-Klita T, Leibschan J. [The effect of tobacco

- 1
2
3 smoking during pregnancy on concentration of uric acid in matched-maternal cord pairs]. *Przeegl Lek.* 2007;**64**(10):667-670.
- 4
5
6 [19] Hakoda M. [Epidemiology of hyperuricemia and gout in Japan]. *Nihon Rinsho.* 2008;**66**(4):647-652.
- 7 [20] Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med.* 2007;**120**(5):442-447 'doi': 10.1016/j.amjmed.2006.06.040.
- 8
9 [21] Yuan H, Yu C, Li X, Sun L, et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. *J Clin Endocrinol Metab.* 2015;**100**(11):4198-4207 'doi': 10.1210/jc.2015-2527.
- 10
11 [22] Ruggiero C, Cherubini A, Ble A, Bos AJ, et al. Uric acid and inflammatory markers. *Eur Heart J.* 2006;**27**(10):1174-1181 'doi': 10.1093/eurheartj/ehi879.
- 12
13 [23] Papezikova I, Pekarova M, Kolarova H, Klinke A, et al. Uric acid modulates vascular endothelial function through the down regulation of nitric oxide production. *Free Radic Res.* 2013;**47**(2):82-88 'doi': 10.3109/10715762.2012.747677.
- 14
15 [24] Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. *Am J Epidemiol.* 2012;**176**(2):108-116 'doi': 10.1093/aje/kws002.
- 16
17 [25] Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, et al. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). *Am J Cardiol.* 2011;**108**(9):1272-1276 'doi': 10.1016/j.amjcard.2011.06.043.
- 18
19 [26] Chao TF, Hung CL, Chen SJ, Wang KL, et al. The association between hyperuricemia, left atrial size and new-onset atrial fibrillation. *Int J Cardiol.* 2013;**168**(4):4027-4032 'doi': 10.1016/j.ijcard.2013.06.067.
- 20
21 [27] Huang G, Xu R, Xu J, Liu Y, et al. Hyperuricemia is associated with atrial fibrillation prevalence in very elderly - a community based study in Chengdu, China. *Scientific Reports.* 2018;**8**(1) 'doi': 10.1038/s41598-018-30321-z.
- 22
23 [28] You L, Liu A, Wuyun G, Wu H, Wang P. Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian area. *J Atheroscler Thromb.* 2014;**21**(4):355-365.
- 24
25 [29] Ndrepepa G. Uric acid and cardiovascular disease. *Clin Chim Acta.* 2018; **484**:150-163 'doi': 10.1016/j.cca.2018.05.046.
- 26
27 [30] Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us? *The American Journal of Medicine.* 2005;**118**(8):816-826 'doi': 10.1016/j.amjmed.2005.03.043.
- 28
29 [31] Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. *Hypertension (Dallas, Tex.: 1979).* 2003;**42**(3):247-252 'doi': 10.1161/01.HYP.0000085858.66548.59.
- 30
31 [32] Short RA, Nakagawa T, Tuttle KR, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. *Nature Clinical Practice Nephrology.* 2005;**1**(2):80-86 'doi': 10.1038/nepneph0019.
- 32
33 [33] Niskanen LK, Laaksonen DE, Nyssonen K, Alftan G, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. *Arch Intern Med.* 2004;**164**(14):1546-1551 'doi': 10.1001/archinte.164.14.1546.
- 34
35 [34] Wang R, Song Y, Yan Y, Ding Z. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis. *Atherosclerosis.* 2016;**254**:193-199 'doi': 10.1016/j.atherosclerosis.2016.10.006.
- 36
37 [35] Maruhashi T, Nakashima A, Soga J, Fujimura N, et al. Hyperuricemia is independently associated with endothelial dysfunction in postmenopausal women but not in premenopausal women. *BMJ Open.* 2013;**3**(11):e3659
- 38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

'doi': 10.1136/bmjopen-2013-003659.

For peer review only



Different prevalence of HUA among male and female in stepwise age categories



A, receiver operating characteristic (ROC) curve of HUA or SUA for AF in male; B, ROC curve of HUA or SUA for AF in female;

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

High prevalence of hyperuricemia and its impact on non-valvular atrial fibrillation: The cross-sectional Guangzhou Heart Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028007.R1
Article Type:	Research
Date Submitted by the Author:	21-Feb-2019
Complete List of Authors:	<p>Lin, Wei-dong; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences</p> <p>Deng, Hai; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology</p> <p>Guo, Pi</p> <p>Liu, Fangzhou; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology</p> <p>Chen, Ruyin; Shantou University Medical College, Preventive Medicine</p> <p>Fang, Xianhong; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology</p> <p>Zhan, xianzhang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology</p> <p>Liao, Hongtao; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology</p> <p>Huang, Wenxiang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology</p> <p>Liu, Yang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology</p> <p>Wang, Feng; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences</p> <p>Zheng, Murui; Guangzhou Center for Disease Control and Prevention</p> <p>Liu, Huazhang; Guangzhou Center for Disease Control and Prevention</p> <p>Huang, Jun; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology</p> <p>Wei, Wei; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology</p> <p>Xue, Yumei; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology</p> <p>Wu, Shu-lin; Department of Cardiology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China</p>
Primary Subject Heading:	Epidemiology

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary Subject Heading:	Public health
Keywords:	Cardiac Epidemiology < CARDIOLOGY, EPIDEMIOLOGY, CARDIOLOGY



High prevalence of hyperuricemia and its impact on non-valvular atrial fibrillation: The cross-sectional Guangzhou Heart Study

Weidong Lin^{1, a}, Hai Deng^{1, a}, Pi Guo^{1, b}, Fangzhou Liu^a, Ruyin Chen^c, Xianhong Fang^a, Xianzhang Zhan^a, Hongtao Liao^a, Wenxiang Huang^a, Yang Liu^a, Feng Wang^a, Murui Zheng^d, Huazhang Liu^d, Jun Huang^a, Wei Wei^a, Yumei Xue^{*, a}, Shulin Wu^{*, a}.

^a Department of cardiology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

^b Department of Preventive Medicine, Shantou University Medical College, Shantou, China

^c Department of Clinical Medicine, Shantou University Medical College, Shantou, China

^d Guangzhou Center for Disease Control and Prevention, Guangzhou, China

Address for correspondence:

Yumei Xue, MD

Department of Cardiology

96 Dongchuan Road, Yuexiu District , Guangzhou City , Guangdong Province, China

Phone: +8613570082363

E-Mail: xymgdc@163.com

Shulin Wu, MD, FACC

Department of Cardiology

96 Dongchuan Road, Yuexiu District , Guangzhou City , Guangdong Province, China

Phone: +8613902255336

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

23 E-Mail: drwushulin@163.com

24

25 Word count: 2493

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

For peer review only

1
2
3
4 45 **ABSTRACT**

5
6 46 **Objectives:** There are regional variations in hyperuricemia (HUA) epidemiology. The prevalence
7
8
9 47 of HUA and non-valvular atrial fibrillation (NVAF) in southern China is unknown.

10
11
12 48 **Design:** A cross-sectional study.

13
14 49 **Setting and participants:** A total of 11,488 permanent residents aged 35 or older from urban and
15
16
17 50 rural areas of Guangzhou city were enrolled. A questionnaire was used to compile each
18
19
20 51 participant's demographic information and relevant epidemiological factors for HUA and NVAF.
21
22 52 All participants were assessed using a panel of blood tests and single-lead 24-hour ECG.

23
24
25 53 **Main outcome measures:** HUA was defined as serum uric acid level $>420\mu\text{mol/L}$ in men and
26
27 54 $>360\mu\text{mol/L}$ in women. NVAF was diagnosed per 2014 AHA/ACC/HRS guidelines.

28
29
30 55 **Results:** The prevalence of HUA was 39.6% (44.8% in men and 36.7% in women), and 144
31
32
33 56 residents (1.25%) had NVAF. Prevalence of HUA increased with age in women but remained
34
35
36 57 stably high in men. After adjusting for potential confounders, age, living in urban areas, alcohol
37
38 58 consumption, central obesity, elevated fasting plasma glucose level, elevated blood pressure,
39
40
41 59 lower HDL cholesterol level and elevated triglycerides level were associated with increased risk
42
43
44 60 of HUA. Residents with HUA were at higher risk for NVAF. Serum uric acid level had a modest
45
46
47 61 predictive value for NVAF in women but not men.

48
49 62 **Conclusions:** HUA was highly prevalent among citizens of southern China and was a predictor
50
51 63 of NVAF among women.

52
53 64

54
55
56 65

1
2
3
4 67 **Strengths and limitations of this study:**
5

- 6 68 ● This cross-sectional population-based study investigated the prevalence of hyperuricemia
7
8
9 69 and its impact on that of non-valvular atrial fibrillation.
10
11 70 ● A large cohort from urban and rural areas of Guangzhou was studied.
12
13
14 71 ● The surveyed areas were all randomized to increase reliability.
15
16
17 72 ● Residents aged under 35 years were not included.
18
19
20 73 ● The results of this cross-sectional study need to be validated in prospective studies.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

89 INTRODUCTION

90 The prevalence of hyperuricemia (HUA) ranges from 13.3% to 21.6% and varies by sex and
91 among countries or regions [1, 2]. Local differences are apparent within countries, likely
92 influenced by environmental, climatic, economic status and especially dietary habits variations [3,
93 4]. Although several epidemiological studies reported an association between serum uric acid
94 (SUA) level and cardiovascular conditions such as hypertension, coronary artery disease,
95 vascular dementia, metabolic syndrome, cerebrovascular disease and kidney disease, it was not
96 apparent in others such as the Framingham Heart Study [5].

97 Atrial fibrillation (AF), the most common clinical cardiac arrhythmia, contributes to increased
98 morbidity and mortality especially in the setting of other cardiovascular risk factors [6]. AF
99 disease burden is estimated to reach 9 million cases by 2050 in China [7], with the increasing
100 prevalence of AF being a global health problem [8, 9]. HUA has been associated with AF [10-13];
101 however, prevalence of HUA and its potential association with that of non-valvular AF (NVAF)
102 in the typical southern Chinese city of Guangzhou with its particular combination of dietary
103 habits, economic status and climate remain undefined.

104 The present cross-sectional population-based study aimed to assess the prevalence of HUA and
105 its association with NVAF among Guangzhou residents.

106

107 Materials and methods

108 Study population

109 We conducted a cardiovascular epidemiological survey (the Guangzhou Heart Study) from July
110 2015 to August 2017 in Guangzhou. Two streets (Dadong Street and Baiyun Street) were

1
2
3
4 111 randomly selected to represent urban areas while one street and two towns (Xiaoguwei Street,
5
6 112 Xinzao Town and Nancun Town) were chosen as rural areas. A sample of permanent residents
7
8
9 113 aged 35 or older was selected by cluster sampling in each community of the aforementioned
10
11
12 114 selected areas.

13
14 115 The residents in the study sites were invited to participate in this study by 3-round mobilization
15
16
17 116 via door-to-door visits or telephone appointments. Residents were enrolled if they met all of the
18
19
20 117 following inclusion criteria: 1) registered in the Guangzhou Household Register; 2) aged 35 years
21
22 118 or older; and 3) living in the selected communities for at least 6 months by the day they
23
24
25 119 participated in the survey. Residents were excluded if they had any of the following conditions: 1)
26
27 120 mental or cognitive disorders including dementia, disturbance of understanding, and deaf-mutters;
28
29
30 121 2) mobility difficulties including paraplegia; 3) pregnant or lactating women; 4)
31
32 122 malignant tumors under treatment; 5) temporary residents including renters; or 6) non-responders
33
34
35 123 during the 3-round mobilization.

36
37
38 124 This study was approved by the Guangzhou Medical Ethics Committee of the Chinese Medical
39
40
41 125 Association and was conducted in accordance with the ethical standards of the 1964 Helsinki
42
43 126 Declaration and its later amendments or comparable ethical standards.

44
45
46 127

47 48 128 **Data collection**

49
50
51 129 A structured and interviewer-administered questionnaire was used to survey each participant's
52
53 130 demographic information, medical history, social habits, family history and emotional status.
54
55
56 131 Physical examination including measurement of waist circumference, height, weight, blood
57
58
59 132 pressure, heart rate and body fat was performed using standard instruments and protocols. Blood
60

1
2
3
4 133 samples were collected and tested following standardized procedures by an authorized medical
5
6 134 laboratory. Electrocardiogram (ECG) and 24-hour single-lead ECG were recorded for each
7
8
9 135 participant and reports were assessed by two independent cardiologists; methodological details
10
11
12 136 were as reported by Deng et al. [14]. A total of 29,196 residents were eligible for inclusion, of
13
14 137 whom 12,013 residents participated in the study; the response rate was therefore 41.16%.

15
16
17 138

19 139 **Cohort definition**

20
21
22 140 Subjects were diagnosed with NVAf if they met any of the following criteria: 1) AF pattern in
23
24 141 ECG screening; 2) No AF in ECG screening but positive AF history; and 3) AF episodes in 24
25
26
27 142 hours single-lead ECG recording. All residents with atrial fibrillation underwent cardiac
28
29
30 143 ultrasonography to assess for valvular AF. NVAf was diagnosed as per
31
32
33 144 2014 AHA/ACC/HRS guidelines [6]. ECG and single-lead 24 hours ECG recordings were
34
35
36 145 performed by well-trained physicians, and AF diagnosis was made by two specific
37
38 146 electrophysiological experts. HUA was defined as serum uric acid (SUA) level $>420\mu\text{mol/L}$ in
39
40
41 147 men and $>360\mu\text{mol/L}$ in women. The metabolic syndrome (MetS) was defined as having at least
42
43 148 three out of the five following characteristic signs [7]: abdominal obesity (defined as waist
44
45
46 149 circumference $\geq 90\text{cm}$ for men and $\geq 80\text{cm}$ for women); elevated triglycerides level: $> 150\text{ mg/dL}$
47
48
49 150 (1.7 mmol/L), or specific treatment for this lipid abnormality; reduced HDL cholesterol: < 40
50
51
52 151 mg/dL (1.03 mmol/L) in men and $< 50\text{ mg/dL}$ (1.29 mmol/L) in women, or specific treatment for
53
54
55 152 this lipid abnormality; elevated blood pressure (BP): systolic BP $> 130\text{ mmHg}$ or diastolic BP $>$
56
57
58 153 85 mmHg , or treatment for previously diagnosed hypertension; and elevated fasting plasma
59
60 154 glucose (FPG): FPG $> 100\text{ mg/dL}$ (5.6 mmol/L), or previously diagnosed type 2 diabetes

1
2
3
4 155 mellitus.
5
6

7 156
8

9 157 **Patient and Public Involvement**

10
11
12 158 The role of patients in this study was residents. They were not involved in the development of the
13
14 159 research question and outcome measures. All residents were informed of their right to enquire
15
16
17 160 about their data and test results. If residents were diagnosed with cardiovascular disease, they
18
19
20 161 were notified by phone to present themselves to Guangdong General Hospital for further
21
22 162 treatment.
23
24

25 163

26 27 164 **Statistical analysis**

28
29
30 165 Continuous variables were expressed as mean \pm standard deviation and categorical variables as
31
32 166 number (percentage). Comparisons between groups were made using the Student *t* test or
33
34
35 167 chi-square tests, as appropriate. Multivariable logistic regression models were developed to
36
37
38 168 investigate the risk factors for HUA and the associations between the prevalence of NVAf and
39
40
41 169 HUA. Odds ratio (OR) and corresponding 95% confidence interval (95% CI) were calculated to
42
43 170 assess the associations. Receiver-operating characteristic (ROC) analyses were used to calculate
44
45
46 171 the predictive value of SUA and HUA for NVAf. SAS software version 9.3 (SAS Institute Inc.;
47
48 172 Cary, NC) was used for the statistical analyses. All statistical tests were 2-sided, and a $P < 0.05$
49
50
51 173 was statistically significant.
52

53 174

54 55 56 175 **RESULTS**

57 58 176 **Baseline characteristics** 59 60

1
2
3
4 177 A total of 12,013 patients were enrolled in the study; 175 patients had atrial fibrillation, which
5
6
7 178 was of valvular origin in 31. A total of 494 patients refused to have a blood test., and therefore
8
9
10 179 11,488 patients were included in the statistical analysis. The prevalence of HUA was 39.6%
11
12 180 (44.8% in men and 36.7% in women, Table 1). Prevalence of HUA increased with age in women
13
14 181 but maintained a steady high level in men [Figure 1]. The prevalence of HUA in urban areas was
15
16
17 182 higher than in rural areas (40.9% vs 38.6%, respectively, P=0.003, Figure 2). Based on medical
18
19
20 183 history, the proportion of men with HUA was significantly higher than that of women. Residents
21
22 184 with HUA were significantly older. Regardless of gender, abdominal circumference and body
23
24
25 185 mass index were significantly greater in residents with HUA. Larger proportion of NVAf, HTN,
26
27 186 DM, central obesity, and stroke/transient ischemic attack (TIA) were observed in residents with
28
29
30 187 HUA. In laboratory testing, hemoglobin (HGB), platelet count (PLT), red blood cell count (RBC),
31
32
33 188 and levels of low-density lipoprotein (LDL), cholesterol (CHOL), and fasting plasma glucose
34
35 189 (FGP) were significantly higher while those of creatinine and high-density lipoprotein were
36
37
38 190 significantly lower in residents with HUA. Significant larger proportion of reduced HDL
39
40 191 cholesterol, elevated TG level and MetS were observed in residents with HUA.

42
43
44
45 192

193 **Table1 Baseline characteristics of residents with or without Hyperuricemia**

	Total (n=11488)	HUA (n=4547)	No HUA (n=6941)	P-value
<i>Clinical characteristics</i>				
Male (n, %)	4047(35.2)	1814(39.9)	2233(32.2)	<0.01
Age (yrs)	58.22±11.74	59.98±11.44	57.06±11.79	<0.01
Urban (n, %)	5403(46.9)	2210(48.6)	3193(46.0)	0.01
Systolic Bp (mmhg)	130.51±20.52	134.16±20.39	128.13±20.25	<0.01

1					
2					
3					
4	Diastolic Bp (mmhg)	80.70±11.61	82.30±11.60	79.62±11.49	<0.01
5	Non-valvular AF (n, %)	144(1.3)	91(2.0)	53(0.8)	<0.01
6					
7	Hypertension (n, %)	3377(29.4)	1744(38.4)	1633(23.5)	<0.01
8					
9	Diabetes mellitus (n, %)	1050(9.1)	528(11.6)	522(7.5)	<0.01
10					
11	Elevated BP (n, %) &	6698(58.3)	3092(68.0)	3606(52.0)	<0.01
12					
13	BMI (kg/m ²)	24.01±3.55	25.08±3.55	23.32±3.37	<0.01
14					
15	Abdominal circumference (cm)	84.41±10.10	87.69±9.61	82.26±9.83	<0.01
16					
17	Male	84.41±10.11	87.71±9.63	82.26±9.83	<0.01
18					
19	Female	82.76±9.98	86.36±9.64	80.66±9.56	<0.01
20					
21	Central obesity (n, %) §	6183(53.8)	2984(65.6)	3199(46.1)	<0.01
22					
23	Heart failure (n, %)	114(1.0)	50(1.1)	64(0.9)	0.39
24					
25	Stroke/TIA (n, %)	274(2.4)	128(2.8)	146(2.1)	0.02
26					
27	Alcohol consumption (n, %)	2467(21.5)	1060(23.3)	1391(20.0)	<0.01
28					
29	Smoking (n, %)	2451(21.3)	1114(24.5)	1353(19.5)	<0.01
30					
31	Laboratory examinations				
32					
33	HGB (g/L)	138.74±14.07	140.14±14.11	137.83±13.97	<0.01
34					
35	PLT (10 ⁹ /L)	243.78±60.67	245.42±61.76	242.71±59.93	0.019
36					
37	RBC (10 ¹² /L)	4.76±0.64	4.80±0.65	4.73±0.63	<0.01
38					
39	HDL cholesterol(mmol/L)	1.49±0.55	1.36±0.51	1.58±0.56	<0.01
40					
41	Reduced HDL cholesterol (n, %) □	2589(22.5)	1369(30.1)	1220(17.6)	<0.01
42					
43	LDL (mmol/L)	3.64±1.03	3.72±1.04	3.58±1.01	<0.01
44					
45	CHOL (mmol/L)	5.486±1.13	5.57±1.17	5.42±1.11	<0.01
46					
47	TG (mmol/L)	1.696±1.43	1.47±1.06	2.05±1.18	<0.01
48					
49	Raised TG level (n, %) £	3787(33.0)	2140(47.1)	1647(23.7)	<0.01
50					
51	FPG (mmol/L)	5.586±1.57	5.69±1.52	5.51±1.60	<0.01
52					
53	Elevated FPG (n, %) ¶	3375(29.4)	1653(36.4)	1722(24.8)	<0.01
54					
55	Uric acid (umol/L)	367.20±98.39	460.60±72.77	306.01±55.62	<0.01
56					
57	Male	367.00±98.30	460.60±72.70	306.01±55.63	<0.01
58					
59	Female	340.76±89.40	434.37±64.43	286.30±46.52	<0.01
60					

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Creatinine(umol/L)	76.89±25.45	83.78±33.25	72.36±17.22	<0.01
--------------------	-------------	-------------	-------------	-------

194 BP: Blood pressure; TIA: Transient Ischemic Attack; BMI: Body Mass Index; HGB: Hemoglobin; PLT: Platelet; RBC: Red
195 blood cell counts; FPG: fasting plasma glucose; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein;
196 CHOL: Cholesterol; Mets: Metabolic syndrome

197 §: Central obesity was defined as waist circumference >85cm for men and >80cm for women

198 ¶: Elevated FPG was defined as fasting plasma glucose > 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes.

199 &: Elevated BP was defined as systolic BP > 130 or diastolic BP > 85 mm Hg or history of hypertension

200 □: Reduced HDL was defined as HDL <40 mg/dL (1.03 mmol/L) in men or <50 mg/dL (1.29 mmol/L) in women or specific
201 treatment for this lipid abnormality.

202 £: Raised Triglycerides level was defined as Triglycerides > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid
203 abnormality.

204

205 Analysis of prevalence risk of hyperuricemia.

206 We performed logistic regression analyses to evaluate the risk factors for hyperuricemia (Table
207 2). After adjusting for possible confounders, age (per 10years, OR 1.10, 95% CI 1.06-1.14),
208 living region (urban, OR 1.15, 95% CI 1.06-1.25), alcohol consumption (OR 1.12, 95% CI
209 1.01-1.24), central obesity (OR 1.82, 95% CI 1.67-1.99), elevated FPG (OR 1.18, 95% CI
210 1.08-1.29), elevated BP (OR 1.34, 95% CI 1.22-1.46), reduced HDL (OR 1.27, 95% CI
211 1.15-1.71), and elevated triglycerides level (OR 2.14, 95% CI 1.97-2.35) were strongly
212 associated with risk for hyperuricemia.

213

214 **Table2. Analysis of prevalence risk of hyperuricemia in multiple logistic regression model.**

Model [†]	Odds ratio	95% confidence interval	P-value
Age (per 10years)	1.10	1.06-1.14	<0.01
Living area(urban)	1.15	1.06-1.25	<0.01
Alcohol consumption	1.12	1.01-1.24	0.03
Central obesity §	1.82	1.67-1.99	<0.01
Elevated FPG ¶	1.18	1.08-1.29	<0.01
Elevated BP &	1.34	1.22-1.46	<0.01

Reduced HDL □	1.27	1.15-1.41	<0.01
Raised Triglycerides level £	2.14	1.96-2.35	<0.01

215 FPG: fasting plasma glucose; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CHOL:

216 Cholesterol;

217 ‡ Adjusted risk factors: age (per 10years), living region, education level, marriage status, smoking status, alcohol consumption,
218 central obesity, Elevated FPG, Elevated BP, Reduced HDL, Raised Triglycerides level

219 §: Central obesity was defined as waist circumference >85cm for men and >80cm for women

220 ¶: Elevated FPG was defined as fasting plasma glucose > 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes.

221 &: Elevated BP was defined as systolic BP > 130 or diastolic BP > 85 mm Hg or history of hypertension

222 □: Reduced HDL was defined as HDL <40 mg/dL (1.03 mmol/L) in men or <50 mg/dL (1.29 mmol/L) in women or specific
223 treatment for this lipid abnormality.

224 £: Raised Triglycerides level was defined as Triglycerides > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid
225 abnormality.

226

227 **Predictive value of hyperuricemia on non-valvular AF.**

228 The adjusted multivariable logistic regression analysis showed that age (per 10 years) (OR 2.31,
229 CI 1.93-2.78), female gender (OR 2.21, CI 1.45-3.36), central obesity (OR 1.93, CI
230 1.29-2.90, P<0.01), HUA (OR 2.19, 95% CI 1.53-3.12) and history of heart failure (OR 5.13, CI
231 2.52-10.43) were risk factors for AF prevalence (Table 3). ROC curves were generated for SUA
232 by gender to determine its diagnostic capability for NVAf. The area under the ROC curve (AUC)
233 for SUA was 0.72 (95% CI: 0.79–0.91) in women and 0.58 (95% CI: 0.51–0.62) in men [Figure
234 3].

235

236 **Table3. Increasing odds ratio for non-valvular AF with hyperuricemia.**

Variables ^o	Odds ratio	95% confidence interval	P-value
Age (per 10years)	2.31	1.93-2.78	<0.01

Gender(female)	2.21	1.45-3.36	<0.01
Central obesity	1.93	1.29-2.87	<0.01
HUA	2.19	1.53-3.12	<0.01
Heart failure	5.13	2.53-10.43	<0.01

237 AF: atrial fibrillation; HUA: Hyperuricemia

238 ⊗ Adjusted risk factors: age (per 10years), gender, heart failure, smoking status, alcohol consumption, central obesity, Elevated

239 FPG, Elevated BP, Reduced HDL, Raised Triglycerides level and Hyperuricemia

240

241 **DISCUSSION**

242 The present study had three main findings. Firstly, the prevalence of HUA was 39.6% (44.8% in
 243 men and 36.7% in women) with sex related differences in residents with HUA. Secondly, the age,
 244 living in urban, alcohol consumption, central obesity, elevated FPG, elevated BP, reduced HDL,
 245 and elevated triglycerides level were strongly associated with risk of HUA. Thirdly, residents
 246 with HUA had a markedly increased risk of NVAf, and SUA had moderate predictive value for
 247 NVAf only in women.

248

249 **The prevalence of hyperuricemia**

250 Regional differences in prevalence of HUA have been reported. According to Liu's review [15],
 251 the prevalence of HUA in mainland China from 2000-2014 was 13.3% (19.4% in men and 7.9%
 252 in women). In Chinese publications, prevalence of HUA in Guangdong province ranged from 15
 253 to 20% [15]. The National Health and Nutrition Examination Survey (NHANES) in the United
 254 States documented a 21.2% HUA prevalence in men and 21.6% in women [2] which was similar
 255 to that in Japan and Taiwan [16, 17]. In this study, the prevalence of HUA in Guangzhou area was
 256 39.6% (44.8% in men and 36.7% in women), which was considerably higher than that in

1
2
3
4 257 previous reports. The traditional dietary habits of Guangzhou residents might be one of the
5
6
7 258 important reasons. Sex related differences in HUA prevalence also were observed in our study.
8
9 259 The prevalence of HUA increased with age in women while remaining at a steady high level in
10
11
12 260 men regardless of age. A rapidly increasing prevalence of HUA in women older than 55 years old
13
14
15 261 was observed; the prevalence was similar to or even higher than that of men after 65 years old.
16
17 262 The latter finding might reflect greatly decreased estrogen level in postmenopausal women [18].
18
19
20 263 Estrogen might promote excretion of SUA via its effect on post-secretory tubular reabsorption of
21
22 264 SUA, as confirmed by the effectiveness of hormone replacement therapy in reducing SUA [19, 20].
23
24
25
26

266 **Risk factors of hyperuricemia**

267 Due to the increasing prevalence of HUA, it is of great clinical significance to search for its risk
268 factors. Risk factors for hyperuricemia might vary among ethnic groups. In this study, age,
269 alcohol consumption, central obesity, elevated FPG, elevated BP, reduced HDL and elevated
270 triglycerides level were strongly associated with the risk of HUA. Previous studies showed that
271 hypertriglyceridemia was strongly associated with risk of HUA [21]. Consistent with our study,
272 the Seychelles Heart Study II documented that high serum TG level was the strongest predictor
273 of HUA [22]. The mechanism of hypertriglyceridemia leading to HUA might be related to lifestyle
274 [22] or genetic factors [23]. Central obesity, elevated FPG, elevated BP, reduced HDL and elevated
275 triglycerides level are all diagnostic components of MetS; therefore, hyperuricemia was closely
276 related to MetS. Yuan's study showed that MetS was 10 times higher in individuals with SUA
277 ≥ 10 mg/dL than in adults with SUA < 6 mg/dL and normal body mass index [24]. A meta-analysis
278 of more than fifty-four thousand participants showed that elevated SUA was associated with

1
2
3
4 279 increased risk of MetS [25]. SUA and MetS often accompany each other and promote the
5
6
7 280 occurrence of cardiovascular disease.
8

9 281

11 282 **Hyperuricemia and non-valvular atrial fibrillation**

12
13
14 283 HUA showed a strong relationship with AF in our study. As reported previously, HUA was
15
16
17 284 associated with endothelial dysfunction, oxidative stress, abnormal high levels of inflammatory
18
19
20 285 markers and insulin resistance [26-28]. In the Atherosclerosis Risk In Communities (ARIC) study
21
22 286 [29], HUA was associated with a greater risk of new onset AF. In contrast to our study, the ARIC
23
24
25 287 study enrolled patients aged 45 to 64 years. Another study from Taiwan [30] showed that SUA
26
27
28 288 significantly correlated with left atrial diameter and that HUA was a significant risk factor for
29
30
31 289 new-onset AF in multivariable Cox regression analysis; however, HUA was diagnosed only
32
33
34 290 when individuals suffered from a gout attack, while in the present study asymptomatic patients
35
36
37 291 were not excluded and uric acid metabolism status of residents was assessed by measuring blood
38
39
40 292 uric acid levels in the fasting state. A recent Chinese report also showed that HUA increased AF
41
42
43 293 risk by 2-fold among elderly southwestern residents [31]. Only 7.6% AF residents in the latter
44
45
46 294 study presented with HUA while 63.2% did not so in the present study cohort. Mechanisms
47
48
49 295 underlying the association between uric acid level and AF remain unclear; however, elevated UA
50
51
52 296 has been associated with vasoconstriction, vascular smooth muscle cell proliferation, endothelial
53
54
55 297 dysfunction, oxidative stress, local inflammation and insulin resistance[32].

56
57
58 298 Differences in cardiovascular events rates by gender have been reported[33]. In the study by
59
60 299 Suzuki and the Atherosclerosis Risk in Communities (ARIC) Study, elevated SUA was
300 associated with a higher risk of AF particularly in women. Both SUA and HUA had moderate

1
2
3
4 301 predictive value for AF in the present study. It is worth noting that SUA had higher AUC than
5
6 302 HUA, which indicates a better predictive value for AF for continuous rather than a cutoff for uric
7
8
9 303 acid (UA). As reported previously, the relationship between UA and cardiovascular disease is
10
11
12 304 apparent with normal to high UA serum level (310-330umol/L) [34-36]; each 1mg/ml increase in
13
14
15 305 UA level was associated with 12% to 20% increase in the risk for cardiovascular and all-cause
16
17 306 mortality, respectively [37]. Therefore, UA level might be strongly associated with AF. The bases
18
19
20 307 for sex related differences in HUA and AF remain unknow. HUA has been associated with
21
22
23 308 endothelial dysfunction in post-menopausal women, suggesting that HUA could be an
24
25 309 independent risk factor for cardiovascular disease including AF, particularly among
26
27
28 310 postmenopausal women [38].

29
30
31
32

312 **Limitations**

313 The present study is limited by its cross-sectional design, warranting prospective studies with
34
35
36
37 314 appropriate follow-up to validate findings; and lack of inclusion of residents aged under 35 years
38
39
40 315 whose HUA prevalence remains unknown.

41
42
43
44

317 **CONCLUSIONS**

318 This large-scale cross-sectional study demonstrated a high prevalence of HUA with sex related
47
48
49
50
51 319 differences among Guangzhou residents. Increasing age, living in an urban setting, alcohol
52
53
54 320 consumption and components of MetS increase the risk of HUA. Residents with HUA had a
55
56
57 321 markedly increased risk for AF and the uric acid level had moderate predictive value for NVAF
58
59
60 322 only in women.

1
2
3
4 323
5

6 324 **Contributors**

7
8
9 325 W.L., H.D., Y.X. and S.W. conceived the study, analyzed data, interpreted results and drafted the
10
11
12 326 manuscript. P.G., R.C., F.L., X.F., X.Z., H.L., W.H., Y.L., F.W., M.Z., H.L., J.H., W.W. collected
13
14 327 data and completed the survey.
15
16

17 328

18
19 329 **Acknowledgments**

20
21
22 330 The authors thank all the residents involved in this study for their cooperation.
23
24

25 331

26
27 332 **Declaration of Conflicting Interests**

28
29
30 333 The author(s) declared no potential conflicts of interest with respect to the research, authorship or
31
32 334 publication of this article.
33
34

35 335

36
37 336 **Funding**

38
39
40 337 This work was supported by National Nature Science Foundation of China (No.81370295),
41
42 338 Guangzhou Science and Technology Project (No. 201508020261 and No. 2014Y200196),
43
44 339 Science and Technology Program of Guangdong Province, China (No.2017A020215054),
45
46 340 Science and Technology Planning of Guangzhou City, China (No.2014B070705005).
47
48

49
50 341

51
52
53 342 **DATA SHARING STATEMENT**

54
55
56 343 The data are available from the corresponding author upon reasonable request.
57
58

59 344

60 345

1
2
3 346
4 347
5
6
7 348

References:

- 8 349 [1] B L, T W, Hn Z, Ww Y, et al. The prevalence of hyperuricemia in China: a meta-analysis. BMC public health.
9 350 2011;**11**(1):832 'doi': 10.1186/1471-2458-11-832[BioMed Central Ltd:2011-01-01].
- 10 351 [2] Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National
11 352 Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;**63**(10):3136-3141 'doi':
12 353 10.1002/art.30520[Copyright (c) 2011 by the American College of Rheumatology.:2011-10-01].
- 13 354 [3] Strasak A, Ruttman E, Brant L, Kelleher C, et al. Serum uric acid and risk of cardiovascular mortality: a
14 355 prospective long-term study of 83,683 Austrian men. Clin Chem. 2008;**54**(2):273-284 'doi':
15 356 10.1373/clinchem.2007.094425[2008-02-01].
- 16 357 [4] Ndrepepa G. Uric acid and cardiovascular disease. Clinica Chimica Acta. 2018; **484**:150-163 'doi':
17 358 10.1016/j.cca.2018.05.046[.].
- 18 359 [5] Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;**359**(17):1811-1821 'doi':
19 360 10.1056/NEJMra0800885[2008-10-23].
- 20 361 [6] January CT, Wann LS, Alpert JS, Calkins H, et al. 2014 AHA/ACC/HRS guideline for the management of
21 362 patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart
22 363 Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;**130**(23):2071-2104
23 364 'doi': 10.1161/CIR.000000000000040[2014-12-02].
- 24 365 [7] Hajhosseiny R, Matthews GK, Lip GY. Metabolic syndrome, atrial fibrillation, and stroke: Tackling an
25 366 emerging epidemic. Heart Rhythm. 2015;**12**(11):2332-2343 'doi': 10.1016/j.hrthm.2015.06.038[Copyright (c) 2015
26 367 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.:2015-11-01].
- 27 368 [8] Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The
28 369 Copenhagen Stroke Study. Stroke. 1996;**27**(10):1765-1769[1996-10-01].
- 29 370 [9] Friberg J, Buch P, Scharling H, Gadsbøll N, Jensen GB. Rising rates of hospital admissions for atrial
30 371 fibrillation. Epidemiology. 2003;**14**(6):666-672 'doi': 10.1097/01.ede.0000091649.26364.c0[2003-11-01].
- 31 372 [10] Suzuki S, Sagara K, Otsuka T, Matsuno S, et al. Gender-Specific Relationship Between Serum Uric Acid Level
32 373 and Atrial Fibrillation Prevalence. Circulation Journal. 2012;**76**(3):607-611 'doi': 10.1253/circj.CJ-11-1111[.].
- 33 374 [11] Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial
34 375 fibrillation: A systematic review and meta-analysis. Heart Rhythm. 2014;**11**(7):1102-1108 'doi':
35 376 10.1016/j.hrthm.2014.04.003[.].
- 36 377 [12] Xu X, Du N, Wang R, Wang Y, Cai S. Hyperuricemia is independently associated with increased risk of atrial
37 378 fibrillation: A meta-analysis of cohort studies. International Journal of Cardiology. 2015; **184**:699-702 'doi':
38 379 10.1016/j.ijcard.2015.02.038[.].
- 39 380 [13] Chen Y, Xia Y, Han X, Yang Y, et al. Association between serum uric acid and atrial fibrillation: a
40 381 cross-sectional community-based study in China. BMJ Open. 2017;**7**(12):e19037 'doi':
41 382 10.1136/bmjopen-2017-019037[.].
- 42 383 [14] Deng H, Guo P, Zheng M, Huang J, et al. Epidemiological Characteristics of Atrial Fibrillation in Southern
43 384 China: Results from the Guangzhou Heart Study. Scientific Reports. 2018;**8**(1) 'doi': 10.1038/s41598-018-35928-w[.].
- 44 385 [15] Liu R, Han C, Wu D, Xia X, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to
45 386 2014: A Systematic Review and Meta-Analysis. BioMed Research International. 2015; **2015**:1-12 'doi':
46 387 10.1155/2015/762820[.].
- 47 388 [16] Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S. Hyperuricemia and cardiovascular risk factor

- 1
2
3 389 clustering in a screened cohort in Okinawa, Japan. *Hypertens Res.* 2004;**27**(4):227-2332004-04-01].
- 4 390 [17] Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health
5 391 Survey in Taiwan from 1993-1996 to 2005-2008. *Asia Pac J Clin Nutr.* 2011;**20**(2):301-3082011-01-20].
- 6 392 [18] Guan S, Tang Z, Fang X, Wu X, et al. Prevalence of hyperuricemia among Beijing post-menopausal women in
7 393 10 years. *Arch Gerontol Geriatr.* 2016; **64**:162-166 'doi': 10.1016/j.archger.2016.02.002[Copyright (c) 2016 Elsevier
8 394 Ireland Ltd. All rights reserved.:2016-05-01].
- 9 395 [19] Anton FM, Garcia PJ, Ramos T, Gonzalez P, Ordas J. Sex differences in uric acid metabolism in adults:
10 396 evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. *Metabolism.*
11 397 1986;**35**(4):343-3481986-04-01].
- 12 398 [20] Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone
13 399 replacement therapy in postmenopausal women with hyperuricaemia. *Lancet.* 1999;**354**(9179):650 'doi':
14 400 10.1016/S0140-6736(99)92381-4[1999-08-21].
- 15 401 [21] Liu CS, Li TC, Lin CC. The epidemiology of hyperuricemia in children of Taiwan aborigines. *J Rheumatol.*
16 402 2003;**30**(4):841-8452003-04-01].
- 17 403 [22] Chelchowska M, Ambroszkiewicz J, Gajewska J, Laskowska-Klita T, Leibschang J. [The effect of tobacco
18 404 smoking during pregnancy on concentration of uric acid in matched-maternal cord pairs]. *Przegl Lek.*
19 405 2007;**64**(10):667-6702007-01-20].
- 20 406 [23] Hakoda M. [Epidemiology of hyperuricemia and gout in Japan]. *Nihon Rinsho.*
21 407 2008;**66**(4):647-6522008-04-01].
- 22 408 [24] Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med.*
23 409 2007;**120**(5):442-447 'doi': 10.1016/j.amjmed.2006.06.040[2007-05-01].
- 24 410 [25] Yuan H, Yu C, Li X, Sun L, et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response
25 411 Meta-Analysis of Prospective Studies. *J Clin Endocrinol Metab.* 2015;**100**(11):4198-4207 'doi':
26 412 10.1210/jc.2015-2527[2015-11-01].
- 27 413 [26] Ruggiero C, Cherubini A, Ble A, Bos AJ, et al. Uric acid and inflammatory markers. *Eur Heart J.*
28 414 2006;**27**(10):1174-1181 'doi': 10.1093/eurheartj/ehi879[2006-05-01].
- 29 415 [27] Papezikova I, Pekarova M, Kolarova H, Klinke A, et al. Uric acid modulates vascular endothelial function
30 416 through the down regulation of nitric oxide production. *Free Radic Res.* 2013;**47**(2):82-88 'doi':
31 417 10.3109/10715762.2012.747677[2013-02-01].
- 32 418 [28] Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin
33 419 resistance, prediabetes, and diabetes: a 15-year follow-up study. *Am J Epidemiol.* 2012;**176**(2):108-116 'doi':
34 420 10.1093/aje/kws002[2012-07-15].
- 35 421 [29] Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, et al. Association of serum uric acid with incident atrial
36 422 fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). *Am J Cardiol.* 2011;**108**(9):1272-1276
37 423 'doi': 10.1016/j.amjcard.2011.06.043[Published by Elsevier Inc.:2011-11-01].
- 38 424 [30] Chao TF, Hung CL, Chen SJ, Wang KL, et al. The association between hyperuricemia, left atrial size and
39 425 new-onset atrial fibrillation. *Int J Cardiol.* 2013;**168**(4):4027-4032 'doi': 10.1016/j.ijcard.2013.06.067[(c)
40 426 2013.:2013-10-09].
- 41 427 [31] Huang G, Xu R, Xu J, Liu Y, et al. Hyperuricemia is associated with atrial fibrillation prevalence in very
42 428 elderly - a community based study in Chengdu, China. *Scientific Reports.* 2018;**8**(1) 'doi':
43 429 10.1038/s41598-018-30321-z[.].
- 44 430 [32] Ndrepepa G. Uric acid and cardiovascular disease. *Clin Chim Acta.* 2018; **484**:150-163 'doi':
45 431 10.1016/j.cca.2018.05.046[Copyright (c) 2018 Elsevier B.V. All rights reserved.:2018-09-01].
- 46 432 [33] Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent

- 1
2
3 433 developments, and where do they leave us? *The American Journal of Medicine*. 2005;**118**(8):816-826 'doi':
4 434 10.1016/j.amjmed.2005.03.043['Elsevier Inc:2005-01-01].
- 5
6 435 [34] Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. *Hypertension (Dallas, Tex.: 1979)*.
7 436 2003;**42**(3):247-252 'doi': 10.1161/01.HYP.0000085858.66548.59['American Heart Association, Inc:2003-01-01].
- 8
9 437 [35] Short RA, Nakagawa T, Tuttle KR, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal
10 438 mechanism for the epidemic of the metabolic syndrome. *Nature Clinical Practice Nephrology*. 2005;**1**(2):80-86 'doi':
11 439 10.1038/ncpneph0019['Nature Publishing Group:2005-01-01].
- 12
13 440 [36] Niskanen LK, Laaksonen DE, Nyyssonen K, Alftan G, et al. Uric acid level as a risk factor for cardiovascular
14 441 and all-cause mortality in middle-aged men: a prospective cohort study. *Arch Intern Med*. 2004;**164**(14):1546-1551
15 442 'doi': 10.1001/archinte.164.14.1546['2004-07-26].
- 16
17 443 [37] Wang R, Song Y, Yan Y, Ding Z. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in
18 444 people with suspected or definite coronary artery disease: A meta-analysis. *Atherosclerosis*. 2016;**254**:193-199 'doi':
19 445 10.1016/j.atherosclerosis.2016.10.006['Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.:2016-11-01].
- 20
21 446 [38] Maruhashi T, Nakashima A, Soga J, Fujimura N, et al. Hyperuricemia is independently associated with
22 447 endothelial dysfunction in postmenopausal women but not in premenopausal women. *BMJ Open*. 2013;**3**(11):e3659
23 448 'doi': 10.1136/bmjopen-2013-003659['2013-11-08].
- 24 449

1
2
3 451 **Figure legends**

4
5 452

6
7 453 **Figure 1.** Differential prevalence of hyperuricemia (HUA) among men and women across
8
9 454 10-year age intervals starting at 35.


10
11
12 455

13
14 456 **Figure 2.** Prevalence of hyperuricemia in urban and rural areas.


15
16
17 457

18
19 458 **Figure 3.** Receiver operating characteristic (ROC) curves for determination of predictive value of
20
21 hyperuricemia (HUA) or serum uric acid (SUA) for AF in men (A) and women (B). AUC (area
22
23 459 under curve).
24
25 460


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Different prevalence of HUA among male and female in stepwise age categories



141x57mm (300 x 300 DPI)



A, receiver operating characteristic (ROC) curve of HUA or SUA for AF in male; B, ROC curve of HUA or SUA for AF in female;

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract L48 (b) Provide in the abstract an informative and balanced summary of what was done and what was found L49-L63
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported L90-L100
Objectives	3	State specific objectives, including any prespecified hypotheses L101-L105
Methods		
Study design	4	Present key elements of study design early in the paper L109-L114
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection L115-137
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants L117-L123
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable L139-L155
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group L164-L173
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at L109-L114, L136-L137
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding L165-L166 (b) Describe any methods used to examine subgroups and interactions L166-L171 (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed L136-L137, L177-L179 (b) Give reasons for non-participation at each stage L177-L179 (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders L179-L191 (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures L179-191
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included L206-L212, L228-L234 (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

meaningful time period

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives L242-L247
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias L312-L314
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence L249-L309
Generalisability	21	Discuss the generalisability (external validity) of the study results L317-L321
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based L336-L339

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

High prevalence of hyperuricemia and its impact on non-valvular atrial fibrillation: The cross-sectional Guangzhou Heart Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028007.R2
Article Type:	Research
Date Submitted by the Author:	31-Mar-2019
Complete List of Authors:	<p>Lin, Wei-dong; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences Deng, Hai; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Guo, Pi Liu, Fangzhou; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Chen, Ruyin; Shantou University Medical College, Preventive Medicine Fang, Xianhong; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Zhan, xianzhang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Liao, Hongtao; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Huang, Wenxiang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Liu, Yang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Wang, Feng; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences Zheng, Murui; Guangzhou Center for Disease Control and Prevention Liu, Huazhang; Guangzhou Center for Disease Control and Prevention Huang, Jun; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Wei, Wei; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Xue, Yumei; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Wu, Shu-lin; Department of Cardiology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China</p>
Primary Subject Heading:	Epidemiology

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary Subject Heading:	Public health
Keywords:	Cardiac Epidemiology < CARDIOLOGY, EPIDEMIOLOGY, CARDIOLOGY



High prevalence of hyperuricemia and its impact on non-valvular atrial fibrillation: The cross-sectional Guangzhou Heart Study

Weidong Lin^{1, a}, Hai Deng^{1, a}, Pi Guo^{1, b}, Fangzhou Liu^a, Ruyin Chen^c, Xianhong Fang^a, Xianzhang Zhan^a, Hongtao Liao^a, Wenxiang Huang^a, Yang Liu^a, Feng Wang^a, Murui Zheng^d, Huazhang Liu^d, Jun Huang^a, Wei Wei^a, Yumei Xue^{*, a}, Shulin Wu^{*, a}.

^a Department of cardiology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

^b Department of Preventive Medicine, Shantou University Medical College, Shantou, China

^c Department of Clinical Medicine, Shantou University Medical College, Shantou, China

^d Guangzhou Center for Disease Control and Prevention, Guangzhou, China

Address for correspondence:

Yumei Xue, MD

Department of Cardiology

96 Dongchuan Road, Yuexiu District , Guangzhou City , Guangdong Province, China

Phone: +8613570082363

E-Mail: xymgdc@163.com

Shulin Wu, MD, FACC

Department of Cardiology

96 Dongchuan Road, Yuexiu District , Guangzhou City , Guangdong Province, China

Phone: +8613902255336

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

23 E-Mail: drwushulin@163.com

24

25 Word count: 2493

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

For peer review only

1
2
3
4 45 **ABSTRACT**

5
6 46 **Objectives:** There are country and regional variations in the prevalence of hyperuricemia (HUA).
7
8
9 47 The prevalence of HUA and non-valvular atrial fibrillation (NVAf) in southern China is
10
11
12 48 unknown.

13
14 49 **Design:** A cross-sectional study.

15
16
17 50 **Setting and participants:** A total of 11,488 permanent residents aged 35 or older from urban and
18
19
20 51 rural areas of Guangzhou city were enrolled. A questionnaire was used to compile each
21
22 52 participant's demographic information and relevant epidemiological factors for HUA and NVAf.
23
24
25 53 All participants were assessed using a panel of blood tests and single-lead 24-hour
26
27 54 electrocardiogram.

28
29
30 55 **Main outcome measures:** HUA was defined as serum uric acid level $>420\mu\text{mol/L}$ in men and
31
32 56 $>360\mu\text{mol/L}$ in women. NVAf was diagnosed per guidelines.

33
34
35 57 **Results:** The prevalence of HUA was 39.6% (44.8% in men and 36.7% in women), and 144
36
37 58 residents (1.25%) had NVAf. Prevalence of HUA increased with age in women but remained
38
39
40 59 stably high in men. After adjusting for potential confounders, age, living in urban areas, alcohol
41
42 60 consumption, central obesity, elevated fasting plasma glucose level, elevated blood pressure,
43
44 61 lower high-density lipoprotein cholesterol level and elevated triglycerides level were associated
45
46
47 62 with increased risk of HUA. Residents with HUA were at higher risk for NVAf. Serum uric acid
48
49
50 63 level had a modest predictive value for NVAf in women but not men.

51
52
53 64 **Conclusions:** HUA was highly prevalent among citizens of southern China and was a predictor
54
55
56 65 of NVAf among women.

1
2
3
4 67 **Strengths and limitations of this study:**
5

- 6 68 ● This cross-sectional population-based study investigated the prevalence of hyperuricemia
7
8
9 69 and its impact on that of non-valvular atrial fibrillation.
10
11 70 ● A large cohort from urban and rural areas of Guangzhou was studied.
12
13
14 71 ● The surveyed areas were all randomized to increase reliability.
15
16
17 72 ● Residents aged under 35 years were not included.
18
19
20 73 ● The results of this cross-sectional study need to be validated in prospective studies.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

89 INTRODUCTION

90 The prevalence of hyperuricemia (HUA) ranges from 13.3% to 21.6% and varies by sex and
91 among countries or regions [1, 2]. Local differences are apparent within countries, likely
92 influenced by environmental, climatic, economic status and especially dietary habits variations [3,
93 4]. Although several epidemiological studies reported an association between serum uric acid
94 (SUA) level and cardiovascular conditions such as hypertension, coronary artery disease,
95 vascular dementia, metabolic syndrome, cerebrovascular disease and kidney disease, it was not
96 apparent in others such as the Framingham Heart Study [5].

97 Atrial fibrillation (AF), the most common clinical cardiac arrhythmia, contributes to increased
98 morbidity and mortality especially in the setting of other cardiovascular risk factors [6]. AF
99 disease burden is estimated to reach 9 million cases by 2050 in China [7], with the increasing
100 prevalence of AF being a global health problem [8, 9]. HUA has been associated with AF [10-13];
101 however, prevalence of HUA and its potential association with that of non-valvular AF (NVAF)
102 in the typical southern Chinese city of Guangzhou with its particular combination of dietary
103 habits, economic status and climate remain undefined.

104 The present cross-sectional population-based study aimed to assess the prevalence of HUA and
105 its association with NVAF among Guangzhou residents.

106

107 Materials and methods

108 Study population

109 We conducted a cardiovascular epidemiological survey (the Guangzhou Heart Study) from July
110 2015 to August 2017 in Guangzhou. Two streets (Dadong Street and Baiyun Street) were

1
2
3
4 111 randomly selected to represent urban areas while one street and two towns (Xiaoguwei Street,
5
6 112 Xinzao Town and Nancun Town) were chosen as rural areas. A sample of permanent residents
7
8
9 113 aged 35 or older was selected by cluster sampling in each community of the aforementioned
10
11
12 114 selected areas.

13
14 115 The residents in the study sites were invited to participate in this study by 3-round mobilization
15
16
17 116 via door-to-door visits or telephone appointments. Residents were enrolled if they met all of the
18
19
20 117 following inclusion criteria: 1) registered in the Guangzhou Household Register; 2) aged 35 years
21
22 118 or older; and 3) living in the selected communities for at least 6 months by the day they
23
24
25 119 participated in the survey. Residents were excluded if they had any of the following conditions: 1)
26
27 120 mental or cognitive disorders including dementia, disturbance of understanding, and deaf-mutters;
28
29
30 121 2) mobility difficulties including paraplegia; 3) pregnant or lactating women; 4)
31
32 122 malignant tumors under treatment; 5) temporary residents including renters; or 6) non-responders
33
34
35 123 during the 3-round mobilization.

36
37
38 124 This study was approved by the Guangzhou Medical Ethics Committee of the Chinese Medical
39
40
41 125 Association and was conducted in accordance with the ethical standards of the 1964 Helsinki
42
43 126 Declaration and its later amendments or comparable ethical standards. All residents needed to
44
45
46 127 sign an informed consent prior to the initiation of the study.

47
48
49
50
51 128

129 **Data collection**

52
53 130 A structured and interviewer-administered questionnaire was used to survey each participant's
54
55
56 131 demographic information, medical history, social habits, family history and emotional status.

57
58 132 Physical examination including measurement of waist circumference, height, weight, blood
59
60

1
2
3
4 133 pressure, heart rate and body fat was performed using standard instruments and protocols. Blood
5
6 134 samples were collected and tested following standardized procedures by an authorized medical
7
8
9 135 laboratory. Electrocardiogram (ECG) and 24-hour single-lead ECG were recorded for each
10
11
12 136 participant and reports were assessed by two independent cardiologists; methodological details
13
14 137 were as reported by Deng et al. [14]. A total of 29,196 residents were eligible for inclusion, of
15
16
17 138 whom 12,013 residents participated in the study; the response rate was therefore 41.16%.

18
19
20 139

21 22 140 **Cohort definition**

23
24 141 Subjects were diagnosed with NVAF if they met any of the following criteria: 1) AF pattern in
25
26
27 142 ECG screening; 2) No AF in ECG screening but positive AF history; and 3) AF episodes in 24
28
29
30 143 hours single-lead ECG recording. All residents with atrial fibrillation underwent cardiac
31
32
33 144 ultrasonography to assess for valvular AF. NVAF was diagnosed as per guidelines [6]. ECG and
34
35 145 single-lead 24 hours ECG recordings were performed by well-trained physicians, and AF
36
37
38 146 diagnosis was made by two specific electrophysiological experts. HUA was defined as serum uric
39
40
41 147 acid (SUA) level $>420\mu\text{mol/L}$ in men and $>360\mu\text{mol/L}$ in women. The metabolic syndrome
42
43 148 (MetS) was defined as having at least three out of the five following characteristic signs [7]:
44
45
46 149 abdominal obesity (defined as waist circumference $\geq 90\text{cm}$ for men and $\geq 80\text{cm}$ for women);
47
48
49 150 elevated triglycerides level: $> 150\text{ mg/dL}$ (1.7 mmol/L), or specific treatment for this lipid
50
51
52 151 abnormality; reduced high-density lipoprotein (HDL) cholesterol: $< 40\text{ mg/dL}$ (1.03 mmol/L) in
53
54 152 men and $< 50\text{ mg/dL}$ (1.29 mmol/L) in women, or specific treatment for this lipid abnormality;
55
56 153 elevated blood pressure (BP): systolic BP $> 130\text{ mmHg}$ or diastolic BP $> 85\text{ mmHg}$, or treatment
57
58
59 154 for previously diagnosed hypertension; and elevated fasting plasma glucose (FPG): FPG > 100
60

1
2
3
4 155 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes mellitus.
5
6

7 156
8

9 157 **Patient and Public Involvement**

10
11 158 Residents were not involved in the development of the research question and outcome measures.
12

13
14 159 All residents were informed of their right to enquire about their data and test results. If residents
15

16
17 160 were diagnosed with cardiovascular disease, they were notified by phone to present themselves to
18

19
20 161 Guangdong General Hospital for further treatment.
21

22 162
23

24 163 **Statistical analysis**

25
26 164 Continuous variables were expressed as mean \pm standard deviation and categorical variables as
27

28
29 165 number (percentage). Comparisons between groups were made using the Student *t* test or
30

31
32 166 chi-square tests, as appropriate. Multivariable logistic regression models were developed to
33

34
35 167 investigate the risk factors for HUA and the associations between the prevalence of NVAf and
36

37
38 168 HUA. Odds ratio (OR) and corresponding 95% confidence interval (95% CI) were calculated to
39

40
41 169 assess the associations. Receiver-operating characteristic (ROC) analyses were used to calculate
42

43
44 170 the predictive value of SUA and HUA for NVAf. SAS software version 9.3 (SAS Institute Inc.;
45

46
47 171 Cary, NC) was used for the statistical analyses. All statistical tests were 2-sided, and a $P < 0.05$
48

49
50 172 was statistically significant.
51

52 173
53

54 174 **RESULTS**

55 175 **Baseline characteristics**

56
57 176 A total of 12,013 patients were enrolled in the study; 175 patients had atrial fibrillation, which
58
59
60

1
2
3
4 177 was of valvular origin in 31. A total of 494 patients refused to have a blood test., and therefore
5
6 178 11,488 patients were included in the statistical analysis. The prevalence of HUA was 39.6%
7
8
9 179 (44.8% in men and 36.7% in women, Table 1). Prevalence of HUA increased with age in women
10
11
12 180 but maintained a steady high level in men [Figure 1]. The prevalence of HUA in urban areas was
13
14 181 higher than in rural areas (40.9% vs 38.6%, respectively, P=0.003, Figure 2). Based on medical
15
16
17 182 history, the proportion of men with HUA was significantly higher than that of women. Residents
18
19 183 with HUA were significantly older. Regardless of gender, abdominal circumference and body
20
21
22 184 mass index were significantly greater in residents with HUA. A higher proportion of NVAF,
23
24
25 185 HTN, DM, central obesity, and stroke/transient ischemic attack (TIA) were observed in residents
26
27
28 186 with HUA. In laboratory testing, hemoglobin (HGB), platelet count (PLT), red blood cell count
29
30
31 187 (RBC), and levels of low-density lipoprotein (LDL), cholesterol (CHOL), and fasting plasma
32
33
34 188 glucose (FGP) were significantly higher while those of creatinine and high-density lipoprotein
35
36
37 189 were significantly lower in residents with HUA. Significant larger proportion of reduced HDL
38
39
40 190 cholesterol, elevated TG level and MetS were observed in residents with HUA.

191

192 **Table1 Baseline characteristics of residents with or without Hyperuricemia**

	Total (n=11488)	HUA (n=4547)	No HUA (n=6941)	P-value
<i>Clinical characteristics</i>				
Male (n, %)	4047(35.2)	1814(39.9)	2233(32.2)	<0.01
Age (yrs)	58.22±11.74	59.98±11.44	57.06±11.79	<0.01
Urban (n, %)	5403(46.9)	2210(48.6)	3193(46.0)	0.01
Systolic Bp (mmhg)	130.51±20.52	134.16±20.39	128.13±20.25	<0.01
Diastolic Bp (mmhg)	80.70±11.61	82.30±11.60	79.62±11.49	<0.01
Non-valvular AF (n, %)	144(1.3)	91(2.0)	53(0.8)	<0.01

1					
2					
3					
4	Hypertension (n, %)	3377(29.4)	1744(38.4)	1633(23.5)	<0.01
5	Diabetes mellitus (n, %)	1050(9.1)	528(11.6)	522(7.5)	<0.01
6					
7	Elevated BP (n, %) &	6698(58.3)	3092(68.0)	3606(52.0)	<0.01
8					
9	BMI (kg/m ²)	24.01±3.55	25.08±3.55	23.32±3.37	<0.01
10					
11	Abdominal circumference (cm)	84.41±10.10	87.69±9.61	82.26±9.83	<0.01
12					
13	Male	84.41±10.11	87.71±9.63	82.26±9.83	<0.01
14					
15	Female	82.76±9.98	86.36±9.64	80.66±9.56	<0.01
16					
17	Central obesity (n, %) §	6183(53.8)	2984(65.6)	3199(46.1)	<0.01
18					
19	Heart failure (n, %)	114(1.0)	50(1.1)	64(0.9)	0.39
20					
21	Stroke/TIA (n, %)	274(2.4)	128(2.8)	146(2.1)	0.02
22					
23	Alcohol consumption (n, %)	2467(21.5)	1060(23.3)	1391(20.0)	<0.01
24					
25	Smoking (n, %)	2451(21.3)	1114(24.5)	1353(19.5)	<0.01
26					
27	Laboratory examinations				
28					
29	HGB (g/L)	138.74±14.07	140.14±14.11	137.83±13.97	<0.01
30					
31	PLT (10 ⁹ /L)	243.78±60.67	245.42±61.76	242.71±59.93	0.019
32					
33	RBC (10 ¹² /L)	4.76±0.64	4.80±0.65	4.73±0.63	<0.01
34					
35	HDL cholesterol(mmol/L)	1.49±0.55	1.36±0.51	1.58±0.56	<0.01
36					
37	Reduced HDL cholesterol (n, %) □	2589(22.5)	1369(30.1)	1220(17.6)	<0.01
38					
39	LDL (mmol/L)	3.64±1.03	3.72±1.04	3.58±1.01	<0.01
40					
41	CHOL (mmol/L)	5.486±1.13	5.57±1.17	5.42±1.11	<0.01
42					
43	TG (mmol/L)	1.696±1.43	1.47±1.06	2.05±1.18	<0.01
44					
45	Raised TG level (n, %) £	3787(33.0)	2140(47.1)	1647(23.7)	<0.01
46					
47	FPG (mmol/L)	5.586±1.57	5.69±1.52	5.51±1.60	<0.01
48					
49	Elevated FPG (n, %) ¶	3375(29.4)	1653(36.4)	1722(24.8)	<0.01
50					
51	Uric acid (umol/L)	367.20±98.39	460.60±72.77	306.01±55.62	<0.01
52					
53	Male	367.00±98.30	460.60±72.70	306.01±55.63	<0.01
54					
55	Female	340.76±89.40	434.37±64.43	286.30±46.52	<0.01
56					
57	Creatinine(umol/L)	76.89±25.45	83.78±33.25	72.36±17.22	<0.01

193 BP: Blood pressure; TIA: Transient Ischemic Attack; BMI: Body Mass Index; HGB: Hemoglobin; PLT: Platelet; RBC: Red
 194 blood cell counts; FPG: fasting plasma glucose; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein;

195 CHOL: Cholesterol; Mets: Metabolic syndrome

196 §: Central obesity was defined as waist circumference >85cm for men and >80cm for women

197 ¶: Elevated FPG was defined as fasting plasma glucose > 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes.

198 &: Elevated BP was defined as systolic BP > 130 or diastolic BP > 85 mm Hg or history of hypertension

199 □: Reduced HDL was defined as HDL <40 mg/dL (1.03 mmol/L) in men or <50 mg/dL (1.29 mmol/L) in women or specific
200 treatment for this lipid abnormality.

201 £: Raised Triglycerides level was defined as Triglycerides > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid
202 abnormality.

203

204 Analysis of prevalence risk of hyperuricemia.

205 We performed logistic regression analyses to evaluate the risk factors for hyperuricemia (Table
206 2). After adjusting for possible confounders, age (per 10years, OR 1.10, 95% CI 1.06-1.14),
207 living region (urban, OR 1.15, 95% CI 1.06-1.25), alcohol consumption (OR 1.12, 95% CI
208 1.01-1.24), central obesity (OR 1.82, 95% CI 1.67-1.99), elevated FPG (OR 1.18, 95% CI
209 1.08-1.29), elevated BP (OR 1.34, 95% CI 1.22-1.46), reduced HDL (OR 1.27, 95% CI
210 1.15-1.71), and elevated triglycerides level (OR 2.14, 95% CI 1.97-2.35) were strongly
211 associated with risk for hyperuricemia.

212

213 **Table2. Analysis of prevalence risk of hyperuricemia in multiple logistic regression model.**

Model [†]	Odds ratio	95% confidence interval	P-value
Age (per 10years)	1.10	1.06-1.14	<0.01
Living area(urban)	1.15	1.06-1.25	<0.01
Alcohol consumption	1.12	1.01-1.24	0.03
Central obesity §	1.82	1.67-1.99	<0.01
Elevated FPG ¶	1.18	1.08-1.29	<0.01
Elevated BP &	1.34	1.22-1.46	<0.01
Reduced HDL □	1.27	1.15-1.41	<0.01
Raised Triglycerides level £	2.14	1.96-2.35	<0.01

214 FPG: fasting plasma glucose; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CHOL:

215 Cholesterol;

216 † Adjusted risk factors: age (per 10years), living region, education level, marriage status, smoking status, alcohol consumption,
217 central obesity, Elevated FPG, Elevated BP, Reduced HDL, Raised Triglycerides level

218 §: Central obesity was defined as waist circumference >85cm for men and >80cm for women

219 ¶: Elevated FPG was defined as fasting plasma glucose > 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes.

220 &: Elevated BP was defined as systolic BP > 130 or diastolic BP > 85 mm Hg or history of hypertension

221 □: Reduced HDL was defined as HDL <40 mg/dL (1.03 mmol/L) in men or <50 mg/dL (1.29 mmol/L) in women or specific
222 treatment for this lipid abnormality.

223 £: Raised Triglycerides level was defined as Triglycerides > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid
224 abnormality.

225

226 **Predictive value of hyperuricemia on non-valvular AF.**

227 The adjusted multivariable logistic regression analysis showed that age (per 10 years) (OR 2.31,
228 CI 1.93-2.78), female gender (OR 2.21, CI 1.45-3.36), central obesity (OR 1.93, CI
229 1.29-2.90, $P < 0.01$), HUA (OR 2.19, 95% CI 1.53-3.12) and history of heart failure (OR 5.13, CI
230 2.52-10.43) were risk factors for AF prevalence (Table 3). ROC curves were generated for SUA
231 by gender to determine its diagnostic capability for NVAf. The area under the ROC curve (AUC)
232 for SUA was 0.72 (95% CI: 0.79–0.91) in women and 0.58 (95% CI: 0.51–0.62) in men [Figure
233 3].

234

235 **Table3. Increasing odds ratio for non-valvular AF with hyperuricemia.**

Variables ^o	Odds ratio	95% confidence interval	P-value
Age (per 10years)	2.31	1.93-2.78	<0.01
Gender(female)	2.21	1.45-3.36	<0.01
Central obesity	1.93	1.29-2.87	<0.01
HUA	2.19	1.53-3.12	<0.01

Heart failure	5.13	2.53-10.43	<0.01
----------------------	------	------------	-------

236 AF: atrial fibrillation; HUA: Hyperuricemia

237 ⊗ Adjusted risk factors: age (per 10years), gender, heart failure, smoking status, alcohol consumption, central obesity, Elevated

238 FPG, Elevated BP, Reduced HDL, Raised Triglycerides level and Hyperuricemia

239

240 **DISCUSSION**

241 The present study had three main findings. Firstly, the prevalence of HUA was 39.6% (44.8% in
 242 men and 36.7% in women) with sex related differences in residents with HUA. Secondly, the age,
 243 living in urban, alcohol consumption, central obesity, elevated FPG, elevated BP, reduced HDL,
 244 and elevated triglycerides level were strongly associated with risk of HUA. Thirdly, residents
 245 with HUA had a markedly increased risk of NVAF, and SUA had moderate predictive value for
 246 NVAF only in women.

247

248 **The prevalence of hyperuricemia**

249 Regional differences in prevalence of HUA have been reported. According to Liu's review [15],
 250 the prevalence of HUA in mainland China from 2000-2014 was 13.3% (19.4% in men and 7.9%
 251 in women). In Chinese publications, prevalence of HUA in Guangdong province ranged from 15
 252 to 20% [15]. The National Health and Nutrition Examination Survey (NHANES) in the United
 253 States documented a 21.2% HUA prevalence in men and 21.6% in women [2] which was similar
 254 to that in Japan and Taiwan [16, 17]. In this study, the prevalence of HUA in Guangzhou area was
 255 39.6% (44.8% in men and 36.7% in women), which was considerably higher than that in
 256 previous reports. The traditional dietary habits of Guangzhou residents might be one of the
 257 important reasons. Sex related differences in HUA prevalence also were observed in our study.

1
2
3
4 258 The prevalence of HUA increased with age in women while remaining at a steady high level in
5
6 259 men regardless of age. A rapidly increasing prevalence of HUA in women older than 55 years old
7
8
9 260 was observed; the prevalence was similar to or even higher than that of men after 65 years old.
10
11
12 261 The latter finding might reflect greatly decreased estrogen level in postmenopausal women [18].
13
14 262 Estrogen might promote excretion of SUA via its effect on post-secretory tubular reabsorption of
15
16
17 263 SUA, as confirmed by the effectiveness of hormone replacement therapy in reducing SUA [19, 20].
18
19
20 264

21 22 265 **Risk factors of hyperuricemia**

23
24 266 Due to the increasing prevalence of HUA, it is of great clinical significance to search for its risk
25
26
27 267 factors. Risk factors for hyperuricemia might vary among ethnic groups. In this study, age,
28
29
30 268 alcohol consumption, central obesity, elevated FPG, elevated BP, reduced HDL and elevated
31
32
33 269 triglycerides level were strongly associated with the risk of HUA. Previous studies showed that
34
35
36 270 hypertriglyceridemia was strongly associated with risk of HUA [21]. Consistent with our study,
37
38
39 271 the Seychelles Heart Study II documented that high serum TG level was the strongest predictor
40
41
42 272 of HUA [22]. The mechanism of hypertriglyceridemia leading to HUA might be related to lifestyle
43
44
45 273 [22] or genetic factors [23]. Central obesity, elevated FPG, elevated BP, reduced HDL and elevated
46
47
48 274 triglycerides level are all diagnostic components of MetS; therefore, hyperuricemia was closely
49
50
51 275 related to MetS. Yuan's study showed that MetS was 10 times higher in individuals with SUA
52
53
54 276 ≥ 10 mg/dL than in adults with SUA < 6 mg/dL and normal body mass index [24]. A meta-analysis
55
56
57 277 of more than fifty-four thousand participants showed that elevated SUA was associated with
58
59
60 278 increased risk of MetS [25]. SUA and MetS often accompany each other and promote the
279 occurrence of cardiovascular disease.

1
2
3
4 280

5
6
7 281 **Hyperuricemia and non-valvular atrial fibrillation**

8
9 282 HUA showed a strong relationship with AF in our study. As reported previously, HUA was
10
11 283 associated with endothelial dysfunction, oxidative stress, abnormal high levels of inflammatory
12
13
14 284 markers and insulin resistance [26-28]. In the Atherosclerosis Risk In Communities (ARIC) study
15
16
17 285 [29], HUA was associated with a greater risk of new onset AF. In contrast to our study, the ARIC
18
19
20 286 study enrolled patients aged 45 to 64 years. Another study from Taiwan [30] showed that SUA
21
22 287 significantly correlated with left atrial diameter and that HUA was a significant risk factor for
23
24
25 288 new-onset AF in multivariable Cox regression analysis; however, HUA was diagnosed only
26
27
28 289 when individuals suffered from a gout attack, while in the present study asymptomatic patients
29
30
31 290 were not excluded and uric acid metabolism status of residents was assessed by measuring blood
32
33
34 291 uric acid levels in the fasting state. A recent Chinese report also showed that HUA increased AF
35
36
37 292 risk by 2-fold among elderly southwestern residents [31]. Only 7.6% AF residents in the latter
38
39
40 293 study presented with HUA while 63.2% did not so in the present study cohort. Mechanisms
41
42
43 294 underlying the association between uric acid level and AF remain unclear; however, elevated UA
44
45
46 295 has been associated with vasoconstriction, vascular smooth muscle cell proliferation, endothelial
47
48
49 296 dysfunction, oxidative stress, local inflammation and insulin resistance[32].

50
51 297 Differences in cardiovascular events rates by gender have been reported[33]. In the study by
52
53
54 298 Suzuki and the Atherosclerosis Risk in Communities (ARIC) Study, elevated SUA was
55
56
57 299 associated with a higher risk of AF particularly in women. Both SUA and HUA had moderate
58
59
60 300 predictive value for AF in the present study. It is worth noting that SUA had higher AUC than
301 HUA, which indicates a better predictive value for AF for continuous rather than a cutoff for uric

1
2
3
4 302 acid (UA). As reported previously, the relationship between UA and cardiovascular disease is
5
6 303 apparent with normal to high UA serum level (310-330umol/L) [34-36]; each 1mg/ml increase in
7
8
9 304 UA level was associated with 12% to 20% increase in the risk for cardiovascular and all-cause
10
11 305 mortality, respectively [37]. Therefore, UA level might be strongly associated with AF. The bases
12
13
14 306 for sex related differences in HUA and AF remain unknown. HUA has been associated with
15
16
17 307 endothelial dysfunction in post-menopausal women, suggesting that HUA could be an
18
19 308 independent risk factor for cardiovascular disease including AF, particularly among
20
21
22 309 postmenopausal women [38].
23
24
25 310

311 **Limitations**

312 The present study is limited by its cross-sectional design, warranting prospective studies with
313 appropriate follow-up to validate findings; and lack of inclusion of residents aged under 35 years
314 whose HUA prevalence remains unknown.
315

316 **CONCLUSIONS**

317 This large-scale cross-sectional study demonstrated a high prevalence of HUA with sex related
318 differences among Guangzhou residents. Increasing age, living in an urban setting, alcohol
319 consumption and components of MetS increase the risk of HUA. Residents with HUA had a
320 markedly increased risk for AF and the uric acid level had moderate predictive value for NVA
321 only in women.
322

323 **Contributors**

1
2
3
4 324 W.L., H.D., Y.X. and S.W. conceived the study, analyzed data, interpreted results and drafted the
5
6 325 manuscript. P.G., R.C., F.L., X.F., X.Z., H.L., W.H., Y.L., F.W., M.Z., H.L., J.H., W.W. collected
7
8
9 326 data and completed the survey.
10
11
12 327

13 14 328 **Acknowledgments**

15
16
17 329 The authors thank all the residents involved in this study for their cooperation.
18
19
20 330

21 22 331 **Declaration of Conflicting Interests**

23
24 332 The author(s) declared no potential conflicts of interest with respect to the research, authorship or
25
26
27 333 publication of this article.
28
29
30 334

31 32 335 **Funding**

33
34
35 336 This work was supported by National Nature Science Foundation of China (No.81370295),
36
37 337 Guangzhou Science and Technology Project (No. 201508020261 and No. 2014Y200196),
38
39
40 338 Science and Technology Program of Guangdong Province, China (No.2017A020215054),
41
42
43 339 Science and Technology Planning of Guangzhou City, China (No.2014B070705005).
44
45
46 340

47 48 341 **DATA SHARING STATEMENT**

49
50 342 The data are available from the corresponding author upon reasonable request.
51
52
53 343
54 344
55 345
56 346

57 58 347 **References:**

- 1
2
3 348 [1] B L, T W, Hn Z, Ww Y, et al. The prevalence of hyperuricemia in China: a meta-analysis. BMC public health.
4 349 2011;**11**(1):832 'doi': 10.1186/1471-2458-11-832['BioMed Central Ltd:2011-01-01].
- 5
6 350 [2] Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National
7 351 Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;**63**(10):3136-3141 'doi':
8 352 10.1002/art.30520['Copyright (c) 2011 by the American College of Rheumatology.:2011-10-01].
- 9
10 353 [3] Strasak A, Ruttman E, Brant L, Kelleher C, et al. Serum uric acid and risk of cardiovascular mortality: a
11 354 prospective long-term study of 83,683 Austrian men. Clin Chem. 2008;**54**(2):273-284 'doi':
12 355 10.1373/clinchem.2007.094425['2008-02-01].
- 13
14 356 [4] Ndrepepa G. Uric acid and cardiovascular disease. Clinica Chimica Acta. 2018; **484**:150-163 'doi':
15 357 10.1016/j.cca.2018.05.046['.
- 16
17 358 [5] Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;**359**(17):1811-1821 'doi':
18 359 10.1056/NEJMra0800885['2008-10-23].
- 19
20 360 [6] January CT, Wann LS, Alpert JS, Calkins H, et al. 2014 AHA/ACC/HRS guideline for the management of
21 361 patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart
22 362 Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;**130**(23):2071-2104
23 363 'doi': 10.1161/CIR.000000000000040['2014-12-02].
- 24
25 364 [7] Hajhosseiny R, Matthews GK, Lip GY. Metabolic syndrome, atrial fibrillation, and stroke: Tackling an
26 365 emerging epidemic. Heart Rhythm. 2015;**12**(11):2332-2343 'doi': 10.1016/j.hrthm.2015.06.038['Copyright (c) 2015
27 366 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.:2015-11-01].
- 28
29 367 [8] Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The
30 368 Copenhagen Stroke Study. Stroke. 1996;**27**(10):1765-17691996-10-01].
- 31
32 369 [9] Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial
33 370 fibrillation. Epidemiology. 2003;**14**(6):666-672 'doi': 10.1097/01.ede.0000091649.26364.c0['2003-11-01].
- 34
35 371 [10] Suzuki S, Sagara K, Otsuka T, Matsuno S, et al. Gender-Specific Relationship Between Serum Uric Acid Level
36 372 and Atrial Fibrillation Prevalence. Circulation Journal. 2012;**76**(3):607-611 'doi': 10.1253/circj.CJ-11-1111['.
- 37
38 373 [11] Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial
39 374 fibrillation: A systematic review and meta-analysis. Heart Rhythm. 2014;**11**(7):1102-1108 'doi':
40 375 10.1016/j.hrthm.2014.04.003['.
- 41
42 376 [12] Xu X, Du N, Wang R, Wang Y, Cai S. Hyperuricemia is independently associated with increased risk of atrial
43 377 fibrillation: A meta-analysis of cohort studies. International Journal of Cardiology. 2015; **184**:699-702 'doi':
44 378 10.1016/j.ijcard.2015.02.038['.
- 45
46 379 [13] Chen Y, Xia Y, Han X, Yang Y, et al. Association between serum uric acid and atrial fibrillation: a
47 380 cross-sectional community-based study in China. BMJ Open. 2017;**7**(12):e19037 'doi':
48 381 10.1136/bmjopen-2017-019037['.
- 49
50 382 [14] Deng H, Guo P, Zheng M, Huang J, et al. Epidemiological Characteristics of Atrial Fibrillation in Southern
51 383 China: Results from the Guangzhou Heart Study. Scientific Reports. 2018;**8**(1) 'doi': 10.1038/s41598-018-35928-w['.
- 52
53 384 [15] Liu R, Han C, Wu D, Xia X, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to
54 385 2014: A Systematic Review and Meta-Analysis. BioMed Research International. 2015; **2015**:1-12 'doi':
55 386 10.1155/2015/762820['.
- 56
57 387 [16] Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S. Hyperuricemia and cardiovascular risk factor
58 388 clustering in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;**27**(4):227-2332004-04-01].
- 59
389 [17] Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health
390 Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr. 2011;**20**(2):301-3082011-01-20].
- 391 [18] Guan S, Tang Z, Fang X, Wu X, et al. Prevalence of hyperuricemia among Beijing post-menopausal women in

- 1
2
3 392 10 years. *Arch Gerontol Geriatr.* 2016; **64**:162-166 'doi': 10.1016/j.archger.2016.02.002['Copyright (c) 2016 Elsevier
4 393 Ireland Ltd. All rights reserved.:2016-05-01].
- 5
6 394 [19] Anton FM, Garcia PJ, Ramos T, Gonzalez P, Ordas J. Sex differences in uric acid metabolism in adults:
7 395 evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. *Metabolism.*
8 396 1986;**35**(4):343-3481986-04-01].
- 9
10 397 [20] Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone
11 398 replacement therapy in postmenopausal women with hyperuricaemia. *Lancet.* 1999;**354**(9179):650 'doi':
12 399 10.1016/S0140-6736(99)92381-4['1999-08-21].
- 13
14 400 [21] Liu CS, Li TC, Lin CC. The epidemiology of hyperuricemia in children of Taiwan aborigines. *J Rheumatol.*
15 401 2003;**30**(4):841-8452003-04-01].
- 16
17 402 [22] Chelchowska M, Ambroszkiewicz J, Gajewska J, Laskowska-Klita T, Leibschang J. [The effect of tobacco
18 403 smoking during pregnancy on concentration of uric acid in matched-maternal cord pairs]. *Przegl Lek.*
19 404 2007;**64**(10):667-6702007-01-20].
- 20
21 405 [23] Hakoda M. [Epidemiology of hyperuricemia and gout in Japan]. *Nihon Rinsho.*
22 406 2008;**66**(4):647-6522008-04-01].
- 23
24 407 [24] Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med.*
25 408 2007;**120**(5):442-447 'doi': 10.1016/j.amjmed.2006.06.040['2007-05-01].
- 26
27 409 [25] Yuan H, Yu C, Li X, Sun L, et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response
28 410 Meta-Analysis of Prospective Studies. *J Clin Endocrinol Metab.* 2015;**100**(11):4198-4207 'doi':
29 411 10.1210/jc.2015-2527['2015-11-01].
- 30
31 412 [26] Ruggiero C, Cherubini A, Ble A, Bos AJ, et al. Uric acid and inflammatory markers. *Eur Heart J.*
32 413 2006;**27**(10):1174-1181 'doi': 10.1093/eurheartj/ehi879['2006-05-01].
- 33
34 414 [27] Papezikova I, Pekarova M, Kolarova H, Klinke A, et al. Uric acid modulates vascular endothelial function
35 415 through the down regulation of nitric oxide production. *Free Radic Res.* 2013;**47**(2):82-88 'doi':
36 416 10.3109/10715762.2012.747677['2013-02-01].
- 37
38 417 [28] Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin
39 418 resistance, prediabetes, and diabetes: a 15-year follow-up study. *Am J Epidemiol.* 2012;**176**(2):108-116 'doi':
40 419 10.1093/aje/kws002['2012-07-15].
- 41
42 420 [29] Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, et al. Association of serum uric acid with incident atrial
43 421 fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). *Am J Cardiol.* 2011;**108**(9):1272-1276
44 422 'doi': 10.1016/j.amjcard.2011.06.043['Published by Elsevier Inc.:2011-11-01].
- 45
46 423 [30] Chao TF, Hung CL, Chen SJ, Wang KL, et al. The association between hyperuricemia, left atrial size and
47 424 new-onset atrial fibrillation. *Int J Cardiol.* 2013;**168**(4):4027-4032 'doi': 10.1016/j.ijcard.2013.06.067['(c)
48 425 2013.:2013-10-09].
- 49
50 426 [31] Huang G, Xu R, Xu J, Liu Y, et al. Hyperuricemia is associated with atrial fibrillation prevalence in very
51 427 elderly - a community based study in Chengdu, China. *Scientific Reports.* 2018;**8**(1) 'doi':
52 428 10.1038/s41598-018-30321-z['.
- 53
54 429 [32] Ndrepepa G. Uric acid and cardiovascular disease. *Clin Chim Acta.* 2018; **484**:150-163 'doi':
55 430 10.1016/j.cca.2018.05.046['Copyright (c) 2018 Elsevier B.V. All rights reserved.:2018-09-01].
- 56
57 431 [33] Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent
58 432 developments, and where do they leave us? *The American Journal of Medicine.* 2005;**118**(8):816-826 'doi':
59 433 10.1016/j.amjmed.2005.03.043['Elsevier Inc:2005-01-01].
- 60
434 [34] Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. *Hypertension (Dallas, Tex.: 1979).*
435 2003;**42**(3):247-252 'doi': 10.1161/01.HYP.0000085858.66548.59['American Heart Association, Inc:2003-01-01].

- 1
2
3 436 [35] Short RA, Nakagawa T, Tuttle KR, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal
4 437 mechanism for the epidemic of the metabolic syndrome. *Nature Clinical Practice Nephrology*. 2005;**1**(2):80-86 'doi':
5 438 10.1038/ncpneph0019['Nature Publishing Group:2005-01-01].
6
7 439 [36] Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, et al. Uric acid level as a risk factor for cardiovascular
8 440 and all-cause mortality in middle-aged men: a prospective cohort study. *Arch Intern Med*. 2004;**164**(14):1546-1551
9 441 'doi': 10.1001/archinte.164.14.1546['2004-07-26].
10
11 442 [37] Wang R, Song Y, Yan Y, Ding Z. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in
12 443 people with suspected or definite coronary artery disease: A meta-analysis. *Atherosclerosis*. 2016;**254**:193-199 'doi':
13 444 10.1016/j.atherosclerosis.2016.10.006['Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.:2016-11-01].
14
15 445 [38] Maruhashi T, Nakashima A, Soga J, Fujimura N, et al. Hyperuricemia is independently associated with
16 446 endothelial dysfunction in postmenopausal women but not in premenopausal women. *BMJ Open*. 2013;**3**(11):e3659
17 447 'doi': 10.1136/bmjopen-2013-003659['2013-11-08].
18
19 448

1
2
3 450 **Figure legends**

4 451

5
6 452 **Figure 1.** Differential prevalence of hyperuricemia (HUA) among men and women across
7
8
9 453 10-year age intervals starting at 35.


10
11
12 454

13
14 455 **Figure 2.** Prevalence of hyperuricemia in urban and rural areas.


15
16
17 456

18
19 457 **Figure 3.** Receiver operating characteristic (ROC) curves for determination of predictive value of
20
21
22 458 hyperuricemia (HUA) or serum uric acid (SUA) for AF in men (A) and women (B). AUC (area
23
24
25 459 under curve).


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Different prevalence of HUA among male and female in stepwise age categories



141x57mm (300 x 300 DPI)



A, receiver operating characteristic (ROC) curve of HUA or SUA for AF in male; B, ROC curve of HUA or SUA for AF in female;

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract L48 (b) Provide in the abstract an informative and balanced summary of what was done and what was found L49-L63
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported L90-L100
Objectives	3	State specific objectives, including any prespecified hypotheses L101-L105
Methods		
Study design	4	Present key elements of study design early in the paper L109-L114
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection L115-137
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants L117-L123
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable L139-L155
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group L164-L173
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at L109-L114, L136-L137
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding L165-L166 (b) Describe any methods used to examine subgroups and interactions L166-L171 (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed L136-L137, L177-L179 (b) Give reasons for non-participation at each stage L177-L179 (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders L179-L191 (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures L179-191
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included L206-L212, L228-L234 (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

meaningful time period

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives L242-L247
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias L312-L314
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence L249-L309
Generalisability	21	Discuss the generalisability (external validity) of the study results L317-L321
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based L336-L339

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

High prevalence of hyperuricemia and its impact on non-valvular atrial fibrillation: The cross-sectional Guangzhou (China) Heart Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028007.R3
Article Type:	Research
Date Submitted by the Author:	02-May-2019
Complete List of Authors:	<p>Lin, Wei-dong; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences Deng, Hai; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Guo, Pi; Shantou University Medical College Liu, Fangzhou; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Chen, Ruyin; Shantou University Medical College, Preventive Medicine Fang, Xianhong; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Zhan, xianzhang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Liao, Hongtao; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Huang, Wenxiang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Liu, Yang; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Wang, Feng; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences Zheng, Murui; Guangzhou Center for Disease Control and Prevention Liu, Huazhang; Guangzhou Center for Disease Control and Prevention Huang, Jun; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Wei, Wei; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Xue, Yumei; Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, cardiology Wu, Shu-lin; Department of Cardiology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China</p>
Primary Subject Heading:	Epidemiology

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary Subject Heading:	Public health
Keywords:	Cardiac Epidemiology < CARDIOLOGY, EPIDEMIOLOGY, CARDIOLOGY



High prevalence of hyperuricemia and its impact on non-valvular atrial fibrillation: The cross-sectional Guangzhou (China) Heart Study

Weidong Lin^{1, a}, Hai Deng^{1, a}, Pi Guo^{1, b}, Fangzhou Liu^a, Ruyin Chen^c, Xianhong Fang^a, Xianzhang Zhan^a, Hongtao Liao^a, Wenxiang Huang^a, Yang Liu^a, Feng Wang^a, Murui Zheng^d, Huazhang Liu^d, Jun Huang^a, Wei Wei^a, Yumei Xue^{*, a}, Shulin Wu^{*, a}.

^a Department of cardiology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

^b Department of Preventive Medicine, Shantou University Medical College, Shantou, China

^c Department of Clinical Medicine, Shantou University Medical College, Shantou, China

^d Guangzhou Center for Disease Control and Prevention, Guangzhou, China

Address for correspondence:

Yumei Xue, MD

Department of Cardiology

96 Dongchuan Road, Yuexiu District , Guangzhou City , Guangdong Province, China

Phone: +8613570082363

E-Mail: xymgdc@163.com

Shulin Wu, MD, FACC

Department of Cardiology

96 Dongchuan Road, Yuexiu District , Guangzhou City , Guangdong Province, China

Phone: +8613902255336

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

23 E-Mail: drwushulin@163.com

24

25 Word count: 2708

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

For peer review only

1
2
3
4 45 **ABSTRACT**

5
6 46 **Objectives:** There are country and regional variations in the prevalence of hyperuricemia (HUA).
7
8
9 47 The prevalence of HUA and non-valvular atrial fibrillation (NVAf) in southern China is
10
11
12 48 unknown.

13
14 49 **Design:** A cross-sectional study.

15
16
17 50 **Setting and participants:** A total of 11,488 permanent residents aged 35 or older from urban and
18
19
20 51 rural areas of Guangzhou, China were enrolled. A questionnaire was used to compile each
21
22 52 participant's demographic information and relevant epidemiological factors for HUA and NVAf.
23
24
25 53 All participants were assessed using a panel of blood tests and single-lead 24-hour
26
27 54 electrocardiogram.

28
29
30 55 **Main outcome measures:** HUA was defined as serum uric acid level $>420\mu\text{mol/L}$ in men and
31
32 56 $>360\mu\text{mol/L}$ in women. NVAf was diagnosed per guidelines.

33
34
35 57 **Results:** The prevalence of HUA was 39.6% (44.8% in men and 36.7% in women), and 144
36
37 58 residents (1.25%) had NVAf. Prevalence of HUA increased with age in women but remained
38
39
40 59 stably high in men. After adjusting for potential confounders, age, living in urban areas, alcohol
41
42 60 consumption, central obesity, elevated fasting plasma glucose level, elevated blood pressure,
43
44 61 lower high-density lipoprotein cholesterol level and elevated triglycerides level were associated
45
46
47 62 with increased risk of HUA. Residents with HUA were at higher risk for NVAf. Serum uric acid
48
49
50 63 level had a modest predictive value for NVAf in women but not men.

51
52
53 64 **Conclusions:** HUA was highly prevalent among citizens of southern China and was a predictor
54
55
56 65 of NVAf among women.

1
2
3
4 67 **Strengths and limitations of this study:**
5

- 6 68 ● This cross-sectional population-based study investigated the prevalence of hyperuricemia
7
8 and its impact on that of non-valvular atrial fibrillation.
9 69
10
11 70 ● A large cohort from urban and rural areas of Guangzhou was studied.
12
13
14 71 ● The surveyed areas were all randomized to increase reliability.
15
16
17 72 ● Residents aged under 35 years were not included.
18
19
20 73 ● The results of this cross-sectional study need to be validated in prospective studies.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

89 INTRODUCTION

90 The prevalence of hyperuricemia (HUA) ranges from 13.3% to 21.6% and varies by sex and
91 among countries or regions [1, 2]. Local differences are apparent within countries, likely
92 influenced by environmental, climatic, economic status and especially dietary habits variations [3,
93 4]. Although several epidemiological studies reported an association between serum uric acid
94 (SUA) level and cardiovascular conditions such as hypertension, coronary artery disease,
95 vascular dementia, metabolic syndrome, cerebrovascular disease and kidney disease, it was not
96 apparent in others such as the Framingham Heart Study [5].

97 Atrial fibrillation (AF), the most common clinical cardiac arrhythmia, contributes to increased
98 morbidity and mortality especially in the setting of other cardiovascular risk factors [6]. AF
99 disease burden is estimated to reach 9 million cases by 2050 in China [7], with the increasing
100 prevalence of AF being a global health problem [8, 9]. HUA has been associated with AF [10-13];
101 however, prevalence of HUA and its potential association with that of non-valvular AF (NVAF)
102 in the typical southern Chinese city of Guangzhou with its particular combination of dietary
103 habits, economic status and climate remain undefined.

104 The present cross-sectional population-based study aimed to assess the prevalence of HUA and
105 its association with NVAF among Guangzhou residents.

107 Materials and methods

108 Study population

109 We conducted a cardiovascular epidemiological survey (the Guangzhou Heart Study) from July
110 2015 to August 2017 in Guangzhou. Randomized multistage cluster sampling was used in this

1
2
3
4 111 study. We divide all the 11 districts in Guangzhou into 2 groups: urban group (Yuexiu, Haizhu,
5
6 112 Liwan, Tianhe, and Huangpu District) and rural group (Baiyun, Panyu, Nansha, Huadu,
7
8
9 113 Conghua and Zengchen District). Sealed envelopes with the names of all the districts written on
10
11
12 114 pieces of paper were prepared before the selection. Then, we randomly selected one envelope
13
14
15 115 from each group. Yuexiu District was selected to represent the urban places while Panyu District
16
17 116 was chosen for the rural regions. We selected Xinzao Town, Nancun Town and Xiaoguwei Street
18
19
20 117 to conduct the survey in Panyu District using the same methods above while Dadong Street and
21
22 118 Baiyun Street were chosen in Yuexiu District. Finally, in the same way, 7 residential committees
23
24
25 119 in Dadong Street and Baiyun Street and 17 village committees in Xinzao Town, Nancun Town
26
27 120 and Xiaoguwei Street based on population size. Every subject who was eligible to fit the
28
29
30 121 inclusive criteria in Yuexiu and Panyu District was all included for the study.

31
32
33 122 The residents in the study sites were invited to participate in this study by 3-round mobilization
34
35 123 via door-to-door visits or telephone appointments. For the first-round mobilization, we made
36
37 124 appointments for the survey from door to door. Responsive information was collected to identify
38
39
40 125 who were eligible to join the survey and within the eligible subjects who were willing, reluctant
41
42
43 126 or indecisive to come. In the second-round mobilization, we promoted the residents who were
44
45
46 127 not connected in the same way. At the same time, we continued to have telephone appointments
47
48 128 for people who were willing or indecisive to join the survey but had not come yet and collected
49
50
51 129 the responsive information. During the last round of the mobilization, we mainly made telephone
52
53
54 130 appointments for the eligible rest of the list who still did not come and sum up the latest
55
56
57 131 responsive information. Residents were enrolled if they met all of the following inclusion criteria:
58
59 132 1) registered in the Guangzhou Household Register; 2) aged 35 years or older; and 3) living in
60

1
2
3
4 133 the selected communities for at least 6 months by the day they participated in the survey.
5
6 134 Residents were excluded if they had any of the following conditions: 1) mental or cognitive
7
8
9 135 disorders including dementia, disturbance of understanding, and deaf-mutters; 2) mobility
10
11 136 difficulties including paraplegia; 3) pregnant or lactating women; 4) malignant tumors under
12
13
14 137 treatment; 5) temporary residents including renters; or 6) non-responders during the 3-round
15
16
17 138 mobilization.

18
19 139 This study was approved by the Guangzhou Medical Ethics Committee of the Chinese Medical
20
21 140 Association (No. GDREC2015306H) and was conducted in accordance with the ethical standards
22
23
24 141 of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All
25
26
27 142 residents needed to sign an informed consent prior to the initiation of the study.
28
29

30 143

31 32 144 **Data collection**

33
34
35 145 A structured and interviewer-administered questionnaire was used to survey each participant's
36
37 146 demographic information, medical history, social habits, family history and emotional status.
38
39 147 Physical examination including measurement of waist circumference, height, weight, blood
40
41 148 pressure, heart rate and body fat was performed using standard instruments and protocols. Blood
42
43 149 samples were collected and tested following standardized procedures by an authorized medical
44
45 150 laboratory. Electrocardiogram (ECG) and 24-hour single-lead ECG were recorded for each
46
47 151 participant and reports were assessed by two independent cardiologists; methodological details
48
49 152 were as reported by Deng et al. ^[14]. A total of 29,196 residents were eligible for inclusion, of
50
51 153 whom 12,013 residents participated in the study; the response rate was therefore 41.16%.
52
53
54
55
56
57
58
59
60

155 **Cohort definition**

156 Subjects were diagnosed with NVAF if they met any of the following criteria: 1) AF pattern in
157 ECG screening; 2) No AF in ECG screening but positive AF history; and 3) AF episodes in 24
158 hours single-lead ECG recording. All residents with atrial fibrillation underwent cardiac
159 ultrasonography to assess for valvular AF. NVAF was diagnosed as per guidelines [6]. ECG and
160 single-lead 24 hours ECG recordings were performed by well-trained physicians, and AF
161 diagnosis was made by two specific electrophysiological experts. HUA was defined as serum uric
162 acid (SUA) level $>420\mu\text{mol/L}$ in men and $>360\mu\text{mol/L}$ in women. The metabolic syndrome
163 (MetS) was defined as having at least three out of the five following characteristic signs [7]:
164 abdominal obesity (defined as waist circumference $\geq 90\text{cm}$ for men and $\geq 80\text{cm}$ for women);
165 elevated triglycerides level: $> 150\text{ mg/dL}$ (1.7 mmol/L), or specific treatment for this lipid
166 abnormality; reduced high-density lipoprotein (HDL) cholesterol: $< 40\text{ mg/dL}$ (1.03 mmol/L) in
167 men and $< 50\text{ mg/dL}$ (1.29 mmol/L) in women, or specific treatment for this lipid abnormality;
168 elevated blood pressure (BP): systolic BP $> 130\text{ mmHg}$ or diastolic BP $> 85\text{ mmHg}$, or treatment
169 for previously diagnosed hypertension; and elevated fasting plasma glucose (FPG): FPG > 100
170 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes mellitus.

171

172 **Patient and Public Involvement**

173 Residents were not involved in the development of the research question and outcome measures.
174 All residents were informed of their right to enquire about their data and test results. If residents
175 were diagnosed with cardiovascular disease, they were notified by phone to present themselves to
176 Guangdong General Hospital for further treatment.

1
2
3
4 1775
6 178 **Statistical analysis**

7
8
9 179 Continuous variables were expressed as mean \pm standard deviation and categorical variables as
10
11 180 number (percentage). Comparisons between groups were made using the Student *t* test or
12
13 181 chi-square tests, as appropriate. Multivariable logistic regression models were developed to
14
15 182 investigate the risk factors for HUA and the associations between the prevalence of NVAF and
16
17 183 HUA. Odds ratio (OR) and corresponding 95% confidence interval (95% CI) were calculated to
18
19 184 assess the associations. Receiver-operating characteristic (ROC) analyses were used to calculate
20
21 185 the predictive value of SUA and HUA for NVAF. SAS software version 9.3 (SAS Institute Inc.;
22
23 186 Cary, NC) was used for the statistical analyses. All statistical tests were 2-sided, and a $P < 0.05$
24
25 187 was statistically significant.

26
27
28
29
30
31
32 18833
34
35 189 **RESULTS**36
37 190 **Baseline characteristics**

38
39 191 A total of 12,013 patients were enrolled in the study; 175 patients had atrial fibrillation, which
40
41 192 was of valvular origin in 31. A total of 494 patients refused to have a blood test., and therefore
42
43 193 11,488 patients were included in the statistical analysis. The prevalence of HUA was 39.6%
44
45 194 (44.8% in men and 36.7% in women, Table 1). Prevalence of HUA increased with age in women
46
47 195 but maintained a steady high level in men [Figure 1]. The prevalence of HUA in urban areas was
48
49 196 higher than in rural areas (40.9% vs 38.6%, respectively, $P = 0.003$, Figure 2). Based on medical
50
51 197 history, the proportion of men with HUA was significantly higher than that of women. Residents
52
53 198 with HUA were significantly older. Regardless of gender, abdominal circumference and body
54
55
56
57
58
59
60

199 mass index were significantly greater in residents with HUA. A higher proportion of NVAf,
 200 HTN, DM, central obesity, and stroke/transient ischemic attack (TIA) were observed in residents
 201 with HUA. In laboratory testing, hemoglobin (HGB), platelet count (PLT), red blood cell count
 202 (RBC), and levels of low-density lipoprotein (LDL), cholesterol (CHOL), and fasting plasma
 203 glucose (FGP) were significantly higher while those of creatinine and high-density lipoprotein
 204 were significantly lower in residents with HUA. Significant larger proportion of reduced HDL
 205 cholesterol, elevated TG level and MetS were observed in residents with HUA.

206

207 **Table1 Baseline characteristics of residents with or without Hyperuricemia**

	Total (n=11488)	HUA (n=4547)	No HUA (n=6941)	P-value
<i>Clinical characteristics</i>				
Male (n, %)	4047(35.2)	1814(39.9)	2233(32.2)	<0.01
Age (yrs)	58.22±11.74	59.98±11.44	57.06±11.79	<0.01
Urban (n, %)	5403(46.9)	2210(48.6)	3193(46.0)	0.01
Systolic Bp (mmhg)	130.51±20.52	134.16±20.39	128.13±20.25	<0.01
Diastolic Bp (mmhg)	80.70±11.61	82.30±11.60	79.62±11.49	<0.01
Non-valvular AF (n, %)	144(1.3)	91(2.0)	53(0.8)	<0.01
Hypertension (n, %)	3377(29.4)	1744(38.4)	1633(23.5)	<0.01
Diabetes mellitus (n, %)	1050(9.1)	528(11.6)	522(7.5)	<0.01
Elevated BP (n, %) &	6698(58.3)	3092(68.0)	3606(52.0)	<0.01
BMI (kg/m ²)	24.01±3.55	25.08±3.55	23.32±3.37	<0.01
Abdominal circumference (cm)	84.41±10.10	87.69±9.61	82.26±9.83	<0.01
Male	84.41±10.11	87.71±9.63	82.26±9.83	<0.01
Female	82.76±9.98	86.36±9.64	80.66±9.56	<0.01
Central obesity (n, %) §	6183(53.8)	2984(65.6)	3199(46.1)	<0.01
Heart failure (n, %)	114(1.0)	50(1.1)	64(0.9)	0.39

Stroke/TIA (n, %)	274(2.4)	128(2.8)	146(2.1)	0.02
Alcohol consumption (n, %)	2467(21.5)	1060(23.3)	1391(20.0)	<0.01
Smoking (n, %)	2451(21.3)	1114(24.5)	1353(19.5)	<0.01
Laboratory examinations				
HGB (g/L)	138.74±14.07	140.14±14.11	137.83±13.97	<0.01
PLT (10 ⁹ /L)	243.78±60.67	245.42±61.76	242.71±59.93	0.019
RBC (10 ¹² /L)	4.76±0.64	4.80±0.65	4.73±0.63	<0.01
HDL cholesterol(mmol/L)	1.49±0.55	1.36±0.51	1.58±0.56	<0.01
Reduced HDL cholesterol (n, %) □	2589(22.5)	1369(30.1)	1220(17.6)	<0.01
LDL (mmol/L)	3.64±1.03	3.72±1.04	3.58±1.01	<0.01
CHOL (mmol/L)	5.486±1.13	5.57±1.17	5.42±1.11	<0.01
TG (mmol/L)	1.696±1.43	1.47±1.06	2.05±1.18	<0.01
Raised TG level (n, %) £	3787(33.0)	2140(47.1)	1647(23.7)	<0.01
FPG (mmol/L)	5.586±1.57	5.69±1.52	5.51±1.60	<0.01
Elevated FPG (n, %) ¶	3375(29.4)	1653(36.4)	1722(24.8)	<0.01
Uric acid (umol/L)	367.20±98.39	460.60±72.77	306.01±55.62	<0.01
Male	367.00±98.30	460.60±72.70	306.01±55.63	<0.01
Female	340.76±89.40	434.37±64.43	286.30±46.52	<0.01
Creatinine(umol/L)	76.89±25.45	83.78±33.25	72.36±17.22	<0.01

208 BP: Blood pressure; TIA: Transient Ischemic Attack; BMI: Body Mass Index; HGB: Hemoglobin; PLT: Platelet; RBC: Red
 209 blood cell counts; FPG: fasting plasma glucose; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein;
 210 CHOL: Cholesterol; Mets: Metabolic syndrome

211 §: Central obesity was defined as waist circumference >85cm for men and >80cm for women

212 ¶: Elevated FPG was defined as fasting plasma glucose > 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes.

213 &: Elevated BP was defined as systolic BP > 130 or diastolic BP > 85 mm Hg or history of hypertension

214 □: Reduced HDL was defined as HDL <40 mg/dL (1.03 mmol/L) in men or <50 mg/dL (1.29 mmol/L) in women or specific
 215 treatment for this lipid abnormality.

216 £: Raised Triglycerides level was defined as Triglycerides > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid
 217 abnormality.

218

219 Analysis of prevalence risk of hyperuricemia.

220 We performed logistic regression analyses to evaluate the risk factors for hyperuricemia (Table

2). After adjusting for possible confounders, age (per 10years, OR 1.10, 95% CI 1.06-1.14), living region (urban, OR 1.15, 95% CI 1.06-1.25), alcohol consumption (OR 1.12, 95% CI 1.01-1.24), central obesity (OR 1.82, 95% CI 1.67-1.99), elevated FPG (OR 1.18, 95% CI 1.08-1.29), elevated BP (OR 1.34, 95% CI 1.22-1.46), reduced HDL (OR 1.27, 95% CI 1.15-1.71), and elevated triglycerides level (OR 2.14, 95% CI 1.97-2.35) were strongly associated with risk for hyperuricemia.

Table2. Analysis of prevalence risk of hyperuricemia in multiple logistic regression model.

Model [†]	Odds ratio	95% confidence interval	P-value
Age (per 10years)	1.10	1.06-1.14	<0.01
Living area(urban)	1.15	1.06-1.25	<0.01
Alcohol consumption	1.12	1.01-1.24	0.03
Central obesity §	1.82	1.67-1.99	<0.01
Elevated FPG ¶	1.18	1.08-1.29	<0.01
Elevated BP &	1.34	1.22-1.46	<0.01
Reduced HDL □	1.27	1.15-1.41	<0.01
Raised Triglycerides level £	2.14	1.96-2.35	<0.01

FPG: fasting plasma glucose; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CHOL: Cholesterol;

[†] Adjusted risk factors: age (per 10years), living region, education level, marriage status, smoking status, alcohol consumption, central obesity, Elevated FPG, Elevated BP, Reduced HDL, Raised Triglycerides level

§: Central obesity was defined as waist circumference >85cm for men and >80cm for women

¶: Elevated FPG was defined as fasting plasma glucose > 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes.

&: Elevated BP was defined as systolic BP > 130 or diastolic BP > 85 mm Hg or history of hypertension

□: Reduced HDL was defined as HDL <40 mg/dL (1.03 mmol/L) in men or <50 mg/dL (1.29 mmol/L) in women or specific treatment for this lipid abnormality.

£: Raised Triglycerides level was defined as Triglycerides > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid

239 abnormality.

240

241 **Predictive value of hyperuricemia on non-valvular AF.**

242 The adjusted multivariable logistic regression analysis showed that age (per 10 years) (OR 2.31,
 243 CI 1.93-2.78), female gender (OR 2.21, CI 1.45-3.36), central obesity (OR 1.93, CI
 244 1.29-2.90, $P < 0.01$), HUA (OR 2.19, 95% CI 1.53-3.12) and history of heart failure (OR 5.13, CI
 245 2.52-10.43) were risk factors for AF prevalence (Table 3). ROC curves were generated for SUA
 246 by gender to determine its diagnostic capability for NVAf. The area under the ROC curve (AUC)
 247 for SUA was 0.72 (95% CI: 0.79–0.91) in women and 0.58 (95% CI: 0.51–0.62) in men [Figure
 248 3].

249

250 **Table 3. Increasing odds ratio for non-valvular AF with hyperuricemia.**

Variables [⊗]	Odds ratio	95% confidence interval	P-value
Age (per 10years)	2.31	1.93-2.78	<0.01
Gender(female)	2.21	1.45-3.36	<0.01
Central obesity	1.93	1.29-2.87	<0.01
HUA	2.19	1.53-3.12	<0.01
Heart failure	5.13	2.53-10.43	<0.01

251 AF: atrial fibrillation; HUA: Hyperuricemia

252 [⊗] Adjusted risk factors: age (per 10years), gender, heart failure, smoking status, alcohol consumption, central obesity, Elevated
 253 FPG, Elevated BP, Reduced HDL, Raised Triglycerides level and Hyperuricemia

254

255 **DISCUSSION**

256 The present study had three main findings. Firstly, the prevalence of HUA was 39.6% (44.8% in
 257 men and 36.7% in women) with sex related differences in residents with HUA. Secondly, the age,

1
2
3
4 258 living in urban, alcohol consumption, central obesity, elevated FPG, elevated BP, reduced HDL,
5
6
7 259 and elevated triglycerides level were strongly associated with risk of HUA. Thirdly, residents
8
9 260 with HUA had a markedly increased risk of NVAF, and SUA had moderate predictive value for
10
11
12 261 NVAF only in women.
13

14 262

17 263 **The prevalence of hyperuricemia**

18
19 264 Regional differences in prevalence of HUA have been reported. According to Liu's review [15],
20
21
22 265 the prevalence of HUA in mainland China from 2000-2014 was 13.3% (19.4% in men and 7.9%
23
24
25 266 in women). In Chinese publications, prevalence of HUA in Guangdong province ranged from 15
26
27
28 267 to 20% [15]. The National Health and Nutrition Examination Survey (NHANES) in the United
29
30
31 268 States documented a 21.2% HUA prevalence in men and 21.6% in women [2] which was similar
32
33
34 269 to that in Japan and Taiwan [16, 17]. In this study, the prevalence of HUA in Guangzhou area was
35
36
37 270 39.6% (44.8% in men and 36.7% in women), which was considerably higher than that in
38
39
40 271 previous reports. The traditional dietary habits of Guangzhou residents might be one of the
41
42
43 272 important reasons. Sex related differences in HUA prevalence also were observed in our study.
44
45
46 273 The prevalence of HUA increased with age in women while remaining at a steady high level in
47
48
49 274 men regardless of age. A rapidly increasing prevalence of HUA in women older than 55 years old
50
51
52 275 was observed; the prevalence was similar to or even higher than that of men after 65 years old.
53
54
55 276 The latter finding might reflect greatly decreased estrogen level in postmenopausal women [18].
56
57
58 277 Estrogen might promote excretion of SUA via its effect on post-secretory tubular reabsorption of
59
60 278 SUA, as confirmed by the effectiveness of hormone replacement therapy in reducing SUA [19, 20].
279

280 **Risk factors of hyperuricemia**

281 Due to the increasing prevalence of HUA, it is of great clinical significance to search for its risk
282 factors. Risk factors for hyperuricemia might vary among ethnic groups. In this study, age,
283 alcohol consumption, central obesity, elevated FPG, elevated BP, reduced HDL and elevated
284 triglycerides level were strongly associated with the risk of HUA. Previous studies showed that
285 hypertriglyceridemia was strongly associated with risk of HUA [21]. Consistent with our study,
286 the Seychelles Heart Study II documented that high serum TG level was the strongest predictor
287 of HUA [22]. The mechanism of hypertriglyceridemia leading to HUA might be related to lifestyle
288 [22] or genetic factors [23]. Central obesity, elevated FPG, elevated BP, reduced HDL and elevated
289 triglycerides level are all diagnostic components of MetS; therefore, hyperuricemia was closely
290 related to MetS. Yuan's study showed that MetS was 10 times higher in individuals with SUA
291 ≥ 10 mg/dL than in adults with SUA < 6 mg/dL and normal body mass index [24]. A meta-analysis
292 of more than fifty-four thousand participants showed that elevated SUA was associated with
293 increased risk of MetS [25]. SUA and MetS often accompany each other and promote the
294 occurrence of cardiovascular disease.

296 **Hyperuricemia and non-valvular atrial fibrillation**

297 HUA showed a strong relationship with AF in our study. As reported previously, HUA was
298 associated with endothelial dysfunction, oxidative stress, abnormal high levels of inflammatory
299 markers and insulin resistance [26-28]. In the Atherosclerosis Risk In Communities (ARIC) study
300 [29], HUA was associated with a greater risk of new onset AF. In contrast to our study, the ARIC
301 study enrolled patients aged 45 to 64 years. Another study from Taiwan [30] showed that SUA

1
2
3
4 302 significantly correlated with left atrial diameter and that HUA was a significant risk factor for
5
6
7 303 new-onset AF in multivariable Cox regression analysis; however, HUA was diagnosed only
8
9
10 304 when individuals suffered from a gout attack, while in the present study asymptomatic patients
11
12 305 were not excluded and uric acid metabolism status of residents was assessed by measuring blood
13
14 306 uric acid levels in the fasting state. A recent Chinese report also showed that HUA increased AF
15
16 307 risk by 2-fold among elderly southwestern residents [31]. Only 7.6% AF residents in the latter
17
18 308 study presented with HUA while 63.2% did not so in the present study cohort. Mechanisms
19
20 309 underlying the association between uric acid level and AF remain unclear; however, elevated UA
21
22 310 has been associated with vasoconstriction, vascular smooth muscle cell proliferation, endothelial
23
24 311 dysfunction, oxidative stress, local inflammation and insulin resistance[32].
25
26
27 312 Differences in cardiovascular events rates by gender have been reported[33]. In the study by
28
29 313 Suzuki and the Atherosclerosis Risk in Communities (ARIC) Study, elevated SUA was
30
31 314 associated with a higher risk of AF particularly in women. Both SUA and HUA had moderate
32
33 315 predictive value for AF in the present study. It is worth noting that SUA had higher AUC than
34
35 316 HUA, which indicates a better predictive value for AF for continuous rather than a cutoff for uric
36
37 317 acid (UA). As reported previously, the relationship between UA and cardiovascular disease is
38
39 318 apparent with normal to high UA serum level (310-330umol/L) [34-36]; each 1mg/ml increase in
40
41 319 UA level was associated with 12% to 20% increase in the risk for cardiovascular and all-cause
42
43 320 mortality, respectively [37]. Therefore, UA level might be strongly associated with AF. The bases
44
45 321 for sex related differences in HUA and AF remain unknown. HUA has been associated with
46
47 322 endothelial dysfunction in post-menopausal women, suggesting that HUA could be an
48
49 323 independent risk factor for cardiovascular disease including AF, particularly among
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 324 postmenopausal women [38].
5
6

7 325
8

9 326 **Limitations**

10
11 327 The present study is limited by its cross-sectional design, warranting prospective studies with
12
13 328 appropriate follow-up to validate findings; and lack of inclusion of residents aged under 35 years
14
15
16 329 whose HUA prevalence remains unknown.
17
18

19 330
20

21
22 331 **CONCLUSIONS**

23
24 332 This large-scale cross-sectional study demonstrated a high prevalence of HUA with sex related
25
26 333 differences among Guangzhou residents. Increasing age, living in an urban setting, alcohol
27
28 334 consumption and components of MetS increase the risk of HUA. Residents with HUA had a
29
30 335 markedly increased risk for AF and the uric acid level had moderate predictive value for NVA
31
32 336 only in women.
33
34
35
36

37 337
38

39 338 **Contributors**

40
41 339 W.L., H.D., Y.X. and S.W. conceived the study, analyzed data, interpreted results and drafted the
42
43 340 manuscript. P.G., R.C., F.L., X.F., X.Z., H.L., W.H., Y.L., F.W., M.Z., H.L., J.H., W.W. collected
44
45
46 341 data and completed the survey.
47
48
49

50 342
51

52
53 343 **Acknowledgments**

54
55 344 The authors thank all the residents involved in this study for their cooperation.
56
57

58 345
59
60

346 **Declaration of Conflicting Interests**

347 The author(s) declared no potential conflicts of interest with respect to the research, authorship or
348 publication of this article.

350 **Funding**

351 This work was supported by National Nature Science Foundation of China (No.81370295),
352 Guangzhou Science and Technology Project (No. 201508020261 and No. 2014Y200196),
353 Science and Technology Program of Guangdong Province, China (No.2017A020215054),
354 Science and Technology Planning of Guangzhou City, China (No.2014B070705005).

356 **DATA SHARING STATEMENT**

357 The data are available from the corresponding author upon reasonable request.

362 **References:**

- 363 [1] B L, T W, Hn Z, Ww Y, et al. The prevalence of hyperuricemia in China: a meta-analysis. BMC public health.
364 2011;**11**(1):832 'doi': 10.1186/1471-2458-11-832[BioMed Central Ltd:2011-01-01].
- 365 [2] Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National
366 Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;**63**(10):3136-3141 'doi':
367 10.1002/art.30520[Copyright (c) 2011 by the American College of Rheumatology.:2011-10-01].
- 368 [3] Strasak A, Ruttman E, Brant L, Kelleher C, et al. Serum uric acid and risk of cardiovascular mortality: a
369 prospective long-term study of 83,683 Austrian men. Clin Chem. 2008;**54**(2):273-284 'doi':
370 10.1373/clinchem.2007.094425[2008-02-01].
- 371 [4] Ndrepepa G. Uric acid and cardiovascular disease. Clinica Chimica Acta. 2018; **484**:150-163 'doi':
372 10.1016/j.cca.2018.05.046[.
- 373 [5] Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;**359**(17):1811-1821 'doi':
374 10.1056/NEJMra0800885[2008-10-23].
- 375 [6] January CT, Wann LS, Alpert JS, Calkins H, et al. 2014 AHA/ACC/HRS guideline for the management of
376 patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart

- 377 Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation*. 2014;**130**(23):2071-2104
378 'doi': 10.1161/CIR.0000000000000040[2014-12-02].
- 379 [7] Hajhosseiny R, Matthews GK, Lip GY. Metabolic syndrome, atrial fibrillation, and stroke: Tackling an
380 emerging epidemic. *Heart Rhythm*. 2015;**12**(11):2332-2343 'doi': 10.1016/j.hrthm.2015.06.038[Copyright (c) 2015
381 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.:2015-11-01].
- 382 [8] Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The
383 Copenhagen Stroke Study. *Stroke*. 1996;**27**(10):1765-1769[1996-10-01].
- 384 [9] Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial
385 fibrillation. *Epidemiology*. 2003;**14**(6):666-672 'doi': 10.1097/01.ede.0000091649.26364.c0[2003-11-01].
- 386 [10] Suzuki S, Sagara K, Otsuka T, Matsuno S, et al. Gender-Specific Relationship Between Serum Uric Acid Level
387 and Atrial Fibrillation Prevalence. *Circulation Journal*. 2012;**76**(3):607-611 'doi': 10.1253/circj.CJ-11-1111[
388 [11] Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial
389 fibrillation: A systematic review and meta-analysis. *Heart Rhythm*. 2014;**11**(7):1102-1108 'doi':
390 10.1016/j.hrthm.2014.04.003[
391 [12] Xu X, Du N, Wang R, Wang Y, Cai S. Hyperuricemia is independently associated with increased risk of atrial
392 fibrillation: A meta-analysis of cohort studies. *International Journal of Cardiology*. 2015; **184**:699-702 'doi':
393 10.1016/j.ijcard.2015.02.038[
394 [13] Chen Y, Xia Y, Han X, Yang Y, et al. Association between serum uric acid and atrial fibrillation: a
395 cross-sectional community-based study in China. *BMJ Open*. 2017;**7**(12):e19037 'doi':
396 10.1136/bmjopen-2017-019037[
397 [14] Deng H, Guo P, Zheng M, Huang J, et al. Epidemiological Characteristics of Atrial Fibrillation in Southern
398 China: Results from the Guangzhou Heart Study. *Scientific Reports*. 2018;**8**(1) 'doi': 10.1038/s41598-018-35928-w[
399 [15] Liu R, Han C, Wu D, Xia X, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to
400 2014: A Systematic Review and Meta-Analysis. *BioMed Research International*. 2015; **2015**:1-12 'doi':
401 10.1155/2015/762820[
402 [16] Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S. Hyperuricemia and cardiovascular risk factor
403 clustering in a screened cohort in Okinawa, Japan. *Hypertens Res*. 2004;**27**(4):227-233[2004-04-01].
- 404 [17] Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health
405 Survey in Taiwan from 1993-1996 to 2005-2008. *Asia Pac J Clin Nutr*. 2011;**20**(2):301-308[2011-01-20].
- 406 [18] Guan S, Tang Z, Fang X, Wu X, et al. Prevalence of hyperuricemia among Beijing post-menopausal women in
407 10 years. *Arch Gerontol Geriatr*. 2016; **64**:162-166 'doi': 10.1016/j.archger.2016.02.002[Copyright (c) 2016 Elsevier
408 Ireland Ltd. All rights reserved.:2016-05-01].
- 409 [19] Anton FM, Garcia PJ, Ramos T, Gonzalez P, Ordas J. Sex differences in uric acid metabolism in adults:
410 evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. *Metabolism*.
411 1986;**35**(4):343-348[1986-04-01].
- 412 [20] Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone
413 replacement therapy in postmenopausal women with hyperuricaemia. *Lancet*. 1999;**354**(9179):650 'doi':
414 10.1016/S0140-6736(99)92381-4[1999-08-21].
- 415 [21] Liu CS, Li TC, Lin CC. The epidemiology of hyperuricemia in children of Taiwan aborigines. *J Rheumatol*.
416 2003;**30**(4):841-845[2003-04-01].
- 417 [22] Chelchowska M, Ambroszkiewicz J, Gajewska J, Laskowska-Klita T, Leibschan J. [The effect of tobacco
418 smoking during pregnancy on concentration of uric acid in matched-maternal cord pairs]. *Przegl Lek*.
419 2007;**64**(10):667-670[2007-01-20].
- 420 [23] Hakoda M. [Epidemiology of hyperuricemia and gout in Japan]. *Nihon Rinsho*.

- 1
2
3 421 2008;**66**(4):647-6522008-04-01].
- 4 422 [24] Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med.*
- 5 423 2007;**120**(5):442-447 'doi': 10.1016/j.amjmed.2006.06.040[2007-05-01].
- 6 424 [25] Yuan H, Yu C, Li X, Sun L, et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response
- 7 425 Meta-Analysis of Prospective Studies. *J Clin Endocrinol Metab.* 2015;**100**(11):4198-4207 'doi':
- 8 426 10.1210/jc.2015-2527[2015-11-01].
- 9 427 [26] Ruggiero C, Cherubini A, Ble A, Bos AJ, et al. Uric acid and inflammatory markers. *Eur Heart J.*
- 10 428 2006;**27**(10):1174-1181 'doi': 10.1093/eurheartj/ehi879[2006-05-01].
- 11 429 [27] Papezikova I, Pekarova M, Kolarova H, Klinke A, et al. Uric acid modulates vascular endothelial function
- 12 430 through the down regulation of nitric oxide production. *Free Radic Res.* 2013;**47**(2):82-88 'doi':
- 13 431 10.3109/10715762.2012.747677[2013-02-01].
- 14 432 [28] Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin
- 15 433 resistance, prediabetes, and diabetes: a 15-year follow-up study. *Am J Epidemiol.* 2012;**176**(2):108-116 'doi':
- 16 434 10.1093/aje/kws002[2012-07-15].
- 17 435 [29] Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, et al. Association of serum uric acid with incident atrial
- 18 436 fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). *Am J Cardiol.* 2011;**108**(9):1272-1276
- 19 437 'doi': 10.1016/j.amjcard.2011.06.043[Published by Elsevier Inc.:2011-11-01].
- 20 438 [30] Chao TF, Hung CL, Chen SJ, Wang KL, et al. The association between hyperuricemia, left atrial size and
- 21 439 new-onset atrial fibrillation. *Int J Cardiol.* 2013;**168**(4):4027-4032 'doi': 10.1016/j.ijcard.2013.06.067[(c)
- 22 440 2013.:2013-10-09].
- 23 441 [31] Huang G, Xu R, Xu J, Liu Y, et al. Hyperuricemia is associated with atrial fibrillation prevalence in very
- 24 442 elderly - a community based study in Chengdu, China. *Scientific Reports.* 2018;**8**(1) 'doi':
- 25 443 10.1038/s41598-018-30321-z[.]
- 26 444 [32] Ndrepepa G. Uric acid and cardiovascular disease. *Clin Chim Acta.* 2018; **484**:150-163 'doi':
- 27 445 10.1016/j.cca.2018.05.046[Copyright (c) 2018 Elsevier B.V. All rights reserved.:2018-09-01].
- 28 446 [33] Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent
- 29 447 developments, and where do they leave us? *The American Journal of Medicine.* 2005;**118**(8):816-826 'doi':
- 30 448 10.1016/j.amjmed.2005.03.043[Elsevier Inc:2005-01-01].
- 31 449 [34] Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. *Hypertension (Dallas, Tex.: 1979).*
- 32 450 2003;**42**(3):247-252 'doi': 10.1161/01.HYP.0000085858.66548.59[American Heart Association, Inc:2003-01-01].
- 33 451 [35] Short RA, Nakagawa T, Tuttle KR, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal
- 34 452 mechanism for the epidemic of the metabolic syndrome. *Nature Clinical Practice Nephrology.* 2005;**1**(2):80-86 'doi':
- 35 453 10.1038/ncpneph0019[Nature Publishing Group:2005-01-01].
- 36 454 [36] Niskanen LK, Laaksonen DE, Nyyssonen K, Alftan G, et al. Uric acid level as a risk factor for cardiovascular
- 37 455 and all-cause mortality in middle-aged men: a prospective cohort study. *Arch Intern Med.* 2004;**164**(14):1546-1551
- 38 456 'doi': 10.1001/archinte.164.14.1546[2004-07-26].
- 39 457 [37] Wang R, Song Y, Yan Y, Ding Z. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in
- 40 458 people with suspected or definite coronary artery disease: A meta-analysis. *Atherosclerosis.* 2016;**254**:193-199 'doi':
- 41 459 10.1016/j.atherosclerosis.2016.10.006[Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.:2016-11-01].
- 42 460 [38] Maruhashi T, Nakashima A, Soga J, Fujimura N, et al. Hyperuricemia is independently associated with
- 43 461 endothelial dysfunction in postmenopausal women but not in premenopausal women. *BMJ Open.* 2013;**3**(11):e3659
- 44 462 'doi': 10.1136/bmjopen-2013-003659[2013-11-08].
- 45 463

1
2
3 465 **Figure legends**

4
5 466

6
7 467 **Figure 1.** Differential prevalence of hyperuricemia (HUA) among men and women across
8
9 468 10-year age intervals starting at 35.


10
11
12 469

13
14 470 **Figure 2.** Prevalence of hyperuricemia in urban and rural areas.


15
16
17 471

18
19 472 **Figure 3.** Receiver operating characteristic (ROC) curves for determination of predictive value of
20
21
22 473 hyperuricemia (HUA) or serum uric acid (SUA) for AF in men (A) and women (B). AUC (area
23
24
25 474 under curve).


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Different prevalence of HUA among male and female in stepwise age categories



141x57mm (300 x 300 DPI)



A, receiver operating characteristic (ROC) curve of HUA or SUA for AF in male; B, ROC curve of HUA or SUA for AF in female;

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract L48 (b) Provide in the abstract an informative and balanced summary of what was done and what was found L49-L63
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported L90-L100
Objectives	3	State specific objectives, including any prespecified hypotheses L101-L105
Methods		
Study design	4	Present key elements of study design early in the paper L109-L114
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection L115-137
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants L117-L123
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable L139-L155
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group L164-L173
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at L109-L114, L136-L137
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding L165-L166 (b) Describe any methods used to examine subgroups and interactions L166-L171 (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed L136-L137, L177-L179 (b) Give reasons for non-participation at each stage L177-L179 (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders L179-L191 (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures L179-191
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included L206-L212, L228-L234 (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

meaningful time period

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives L242-L247
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias L312-L314
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence L249-L309
Generalisability	21	Discuss the generalisability (external validity) of the study results L317-L321
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based L336-L339

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.